Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2017 | Nov. 06, 2017 | |
Document and Entity Information | ||
Entity Registrant Name | BRUKER CORP | |
Entity Central Index Key | 1,109,354 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 155,562,660 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 |
Current assets: | ||
Cash and cash equivalents | $ 263.9 | $ 342.4 |
Short-term investments | 165.3 | 157.9 |
Accounts receivable, net | 269.8 | 243.9 |
Inventories | 515.3 | 440.4 |
Other current assets | 122.5 | 91.3 |
Total current assets | 1,336.8 | 1,275.9 |
Property, plant and equipment, net | 260.4 | 239.1 |
Goodwill | 168.6 | 130.6 |
Intangibles, net and other long-term assets | 195.7 | 162.8 |
Total assets | 1,961.5 | 1,808.4 |
Current liabilities: | ||
Current portion of long-term debt | 20.1 | |
Accounts payable | 94.8 | 86.1 |
Customer advances | 126.2 | 149 |
Other current liabilities | 292.5 | 269.5 |
Total current liabilities | 513.5 | 524.7 |
Long-term debt | 480.5 | 391.6 |
Other long-term liabilities | 227.6 | 199 |
Commitments and contingencies (Note 11) | ||
Shareholders' equity: | ||
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding | ||
Common stock, $0.01 par value 260,000,000 shares authorized, 171,522,516 and 170,552,890 shares issued and 156,173,417 and 159,854,695 shares outstanding at September 30, 2017 and December 31, 2016, respectively | 1.7 | 1.7 |
Treasury stock, at cost, 15,349,099 and 10,698,195 shares at September 30, 2017 and December 31, 2016, respectively | (380.9) | (249.3) |
Accumulated other comprehensive income (loss) | 10.5 | (75.9) |
Other shareholders' equity | 1,100.5 | 1,009.9 |
Total shareholders' equity attributable to Bruker Corporation | 731.8 | 686.4 |
Noncontrolling interest in consolidated subsidiaries | 8.1 | 6.7 |
Total shareholders' equity | 739.9 | 693.1 |
Total liabilities and shareholders' equity | $ 1,961.5 | $ 1,808.4 |
CONDENSED CONSOLIDATED BALANCE3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 30, 2017 | Dec. 31, 2016 |
CONDENSED CONSOLIDATED BALANCE SHEETS | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 260,000,000 | 260,000,000 |
Common stock, shares issued | 171,522,516 | 170,552,890 |
Common stock, shares outstanding | 156,173,417 | 159,854,695 |
Treasury stock, shares | 15,349,099 | 10,698,195 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) | ||||
Product revenue | $ 364.4 | $ 328.2 | $ 1,029.2 | $ 946.1 |
Service revenue | 70 | 62.3 | 200.4 | 186.5 |
Other revenue | 1.2 | 3.4 | 5.8 | 8.4 |
Total revenue | 435.6 | 393.9 | 1,235.4 | 1,141 |
Cost of product revenue | 196.5 | 172.2 | 561.8 | 504.7 |
Cost of service revenue | 40.5 | 35.4 | 114.9 | 110.8 |
Cost of other revenue | 0.6 | 1.1 | 0.9 | 3.4 |
Total cost of revenue | 237.6 | 208.7 | 677.6 | 618.9 |
Gross profit | 198 | 185.2 | 557.8 | 522.1 |
Operating expenses: | ||||
Selling, general and administrative | 102.9 | 96.8 | 303.8 | 290.4 |
Research and development | 40.9 | 37.9 | 119.2 | 110.8 |
Other charges, net | 4.3 | 4.6 | 13.8 | 20.6 |
Total operating expenses | 148.1 | 139.3 | 436.8 | 421.8 |
Operating income | 49.9 | 45.9 | 121 | 100.3 |
Interest and other expense, net | (2.5) | (2.9) | (11.8) | (11.1) |
Income before income taxes and noncontrolling interest in consolidated subsidiaries | 47.4 | 43 | 109.2 | 89.2 |
Income tax provision (benefit) | 9.8 | (4) | 25.9 | 3.8 |
Consolidated net income | 37.6 | 47 | 83.3 | 85.4 |
Net income attributable to noncontrolling interest in consolidated subsidiaries | 0.6 | 0.5 | 1.3 | 0.8 |
Net income attributable to Bruker Corporation | $ 37 | $ 46.5 | $ 82 | $ 84.6 |
Net income per common share attributable to Bruker Corporation shareholders: | ||||
Basic (in dollars per share) | $ 0.23 | $ 0.29 | $ 0.52 | $ 0.52 |
Diluted (in dollars per share) | $ 0.23 | $ 0.29 | $ 0.51 | $ 0.52 |
Weighted average common shares outstanding: | ||||
Basic (in shares) | 157.5 | 160.8 | 158.9 | 161.8 |
Diluted (in shares) | 158.7 | 161.5 | 159.9 | 162.7 |
Comprehensive income | $ 61.2 | $ 60.3 | $ 170.3 | $ 114.3 |
Less: Comprehensive income attributable to noncontrolling interests | 0.7 | 0.6 | 1.9 | 0.9 |
Comprehensive income attributable to Bruker Corporation | $ 60.5 | $ 59.7 | $ 168.4 | $ 113.4 |
Dividend declared (in dollars per share) | $ 0.04 | $ 0.04 | $ 0.12 | $ 0.12 |
CONDENSED CONSOLIDATED STATEME5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Cash flows from operating activities: | ||
Consolidated net income | $ 83.3 | $ 85.4 |
Adjustments to reconcile consolidated net income to cash flows from operating activities: | ||
Depreciation and amortization | 48.2 | 40.4 |
Stock-based compensation expense | 8.4 | 6.8 |
Deferred income taxes | (5) | (32.1) |
Other non-cash expenses, net | 6.1 | 25.2 |
Changes in operating assets and liabilities, net of acquisitions and divestitures: | ||
Accounts receivable | (8.4) | 15.4 |
Inventories | (37.5) | (73.4) |
Accounts payable and accrued expenses | (8.6) | (11.5) |
Income taxes payable, net | (6.3) | (19.8) |
Deferred revenue | (0.2) | 3 |
Customer advances | (34.7) | (6.5) |
Other changes in operating assets and liabilities, net | 5.4 | 7.1 |
Net cash provided by operating activities | 50.7 | 40 |
Cash flows from investing activities: | ||
Purchases of short-term investments | (118.5) | (77.6) |
Maturities of short-term investments | 134 | 122.4 |
Cash paid for acquisitions, net of cash acquired | (65.8) | (1.2) |
Purchases of property, plant and equipment | (31.3) | (26) |
Proceeds from sales of property, plant and equipment | 6.9 | 0.9 |
Net cash (used in) provided by investing activities | (74.7) | 18.5 |
Cash flows from financing activities: | ||
Repayments of the Note Purchase Agreement | (20) | |
Repayments of revolving lines of credit | (65) | |
Proceeds from revolving lines of credit | 154 | 99 |
(Repayment) proceeds of other debt, net | (1) | 0.1 |
Proceeds from issuance of common stock, net | 15.3 | 10.2 |
Payment of contingent consideration | (3.5) | |
Repurchase of common stock | (129.7) | (143.5) |
Excess tax benefit related to stock option awards | 0.3 | |
Payment of dividends | (19.1) | (19.4) |
Cash payments to noncontrolling interest | (0.5) | (0.7) |
Net cash used in financing activities | (69.5) | (54) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 15.4 | 6.6 |
Net change in cash, cash equivalents and restricted cash | (78.1) | 11.1 |
Cash, cash equivalents and restricted cash at beginning of period | 345.9 | 271.2 |
Cash, cash equivalents and restricted cash at end of period | $ 267.8 | $ 282.3 |
Description of Business
Description of Business | 9 Months Ended |
Sep. 30, 2017 | |
Description of Business | |
Description of Business | 1. Description of Business Bruker Corporation, together with its consolidated subsidiaries (“Bruker” or the “Company”), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. The Company has two reportable segments, Bruker Scientific Instruments (BSI) , which represented approximately 89.7% and 89.0% of the Company’s revenues during the three and nine months ended September 30, 2017, respectively, and 91.8% and 92.7% of the Company’s revenues during the three and nine months ended September 30, 2016, respectively; and Bruker Energy & Supercon Technologies (BEST) , which represented the remainder of the Company’s revenues. Within BSI, the Company is organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. For financial reporting purposes, the Bruker BioSpin, Bruker CALID and Bruker Nano operating segments are aggregated into the BSI reportable segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments. Bruker BioSpin — The Bruker BioSpin Group designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. The majority of the Bruker BioSpin Group’s revenues are generated by academic and government research customers. Other customers include pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies. Bruker CALID ( C hemicals, A pplied Markets, L ife Science, I n-Vitro Diagnostics, D etection) — The Bruker CALID Group designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry systems, infrared spectroscopy and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection and analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. Customers of the Bruker CALID Group include: academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit or for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies. Bruker Nano — The Bruker Nano Group designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; and spark optical emission spectroscopy systems. Customers of the Bruker Nano Group include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials analysis. The Company’s BEST reportable segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications, as well as ceramic high temperature superconductors primarily for energy grid and magnet applications. The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year. At September 30, 2017, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, have not changed other than the Company no longer considers changes in employee benefit plan assumptions to be a critical accounting policy. In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows, Restricted Cash , requiring restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. The Company adopted this standard during the first quarter of 2017. Restricted cash is now included as a component of cash, cash equivalents, and restricted cash on the Company’s unaudited condensed consolidated statement of cash flows. The Company has certain subsidiaries which are required by local governance to maintain restricted cash balances to cover future employee benefit payments. Restricted cash balances are classified as non-current unless, under the terms of the applicable agreements, the funds will be released from restrictions within one year from the balance sheet date. The current and non-current portion of restricted cash is recorded within other current assets and other long-term assets, respectively, in the accompanying consolidated balance sheets. The inclusion of restricted cash increased the balances of the unaudited condensed consolidated statement of cash flows as follows: Nine Months Ended September 30, 2017 2016 Beginning Balance $ $ Ending Balance |
Acquisitions
Acquisitions | 9 Months Ended |
Sep. 30, 2017 | |
Acquisitions | |
Acquisitions | 2. Acquisitions On May 5, 2017, the Company acquired 100% of the shares of Luxendo GmbH (“Luxendo”), a privately held spin-off of the European Molecular Biology Laboratory, for a purchase price of Euro 17 million (approximately $18.8 million), with the potential for additional consideration based on revenue achievements in 2018 through 2021. Luxendo is a developer and manufacturer of proprietary light-sheet fluorescence microscopy instruments and the Company believes the acquisition enhances the Company’s portfolio of swept-field confocal, super-resolution, and multiphoton fluorescence microscope product lines for small organism embryology, live-cell imaging, brain development and cleared brain tissue and optogenetics applications. Luxendo is located in Heidelberg, Germany and is being integrated into the Bruker Nano Group within the BSI reportable segment. The acquisition of Luxendo was accounted for under the acquisition method. The components and fair value allocation of the consideration transferred in connection with the acquisition were as follows (in millions): Consideration Transferred: Cash paid $ Cash acquired ) Contingent consideration Total consideration transferred $ Allocation of Consideration Transferred: Inventories Other current and non-current assets Property, plant and equipment Intangible assets: Existing technology Trade name Goodwill Deferred taxes, net ) Liabilities assumed ) Total consideration transferred $ The preliminary fair value allocation included contingent consideration in the amount of $3.1 million, which represented the estimated fair value of future payments to the former shareholders of Luxendo based on achieving annual revenue targets for the years 2018 through 2021. The Company completed the fair value allocation in the third quarter of 2017. The amortization period for intangible assets acquired in connection with the acquisition of Luxendo is 10 years for trade names and 7 years for technology. The results of Luxendo, including the amount allocated to goodwill that is attributable to expected synergies and not expected to be deductible for tax purposes, have been included in the BSI Segment from the date of acquisition. Pro forma financial information reflecting the acquisition of Luxendo has not been presented because the impact on revenues, net income and total assets is not material. On January 23, 2017, the Company acquired 100% of the shares of Hysitron, Incorporated (“Hysitron”). The acquisition adds Hysitron’s nanomechanical testing instruments to the Company’s existing portfolio of atomic force microscopes, surface profilometers, and tribology and mechanical testing systems. Hysitron is included in the Bruker Nano Group within the BSI reportable segment. The acquisition of Hysitron was accounted for under the acquisition method. The components and fair value allocation of the consideration transferred in connection with the acquisition of Hysitron were as follows (in millions): Consideration Transferred: Cash paid $ Cash acquired ) Contingent consideration Total consideration transferred $ Allocation of Consideration Transferred: Accounts receivable, net $ Inventories Other current assets Property, plant and equipment Intangible assets: Customer relationships Existing technology Trade name Other Goodwill Deferred taxes, net ) Capital lease ) Liabilities assumed ) Total consideration transferred $ The fair value allocation included contingent consideration in the amount of $1.6 million, which represented the estimated fair value of future payments to the former shareholders of Hysitron based on achieving annual revenue targets for the years 2017 through 2018. The Company completed the fair value allocation in the second quarter of 2017. The maximum potential future payments related to the contingent consideration is $10 million. The amortization period for intangible assets acquired in connection with Hysitron is 7 years for customer relationships, trademarks and other intangibles and 5 years for existing technology. The results of Hysitron, including the amount allocated to goodwill that is attributable to expected synergies and not expected to be deductible for tax purposes, have been included in the BSI Segment from the date of acquisition. Pro forma financial information reflecting the acquisition of Hysitron has not been presented because the impact on revenues, net income and total assets is not material. In addition to the acquisitions noted above, in the nine months ended September 30, 2017, the Company completed various other acquisitions that collectively complemented the Company’s existing product offerings and added aftermarket and software capabilities to the Company’s existing microbiology business. The impact of these acquisitions, individually and collectively, on revenues, net income and total assets was not material. Pro forma financial information reflecting these acquisitions has not been presented because the impact, individually and collectively, on revenues, net income and total assets is not material. |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Sep. 30, 2017 | |
Stock-Based Compensation | |
Stock-Based Compensation | 3. Stock-Based Compensation On May 14, 2010, the Bruker Corporation 2010 Incentive Compensation Plan (the “2010 Plan”) was approved by the Company’s stockholders. The 2010 Plan provided for the issuance of up to 8,000,000 shares of the Company’s common stock. The 2010 Plan allowed a committee of the Board of Directors (the “Compensation Committee”) to grant incentive stock options, non-qualified stock options and restricted stock awards. The Compensation Committee had the authority to determine which employees would receive the awards, the amount of the awards and other terms and conditions of any awards. Awards granted under the 2010 Plan typically were made subject to a vesting period of three to five years. On May 20, 2016, the Bruker Corporation 2016 Incentive Compensation Plan (the “2016 Plan”) was approved by the Company’s stockholders. With the approval of the 2016 Plan, no further grants will be made under the 2010 Plan. The 2016 Plan provides for the issuance of up to 9,500,000 shares of the Company’s common stock and permits the grant of awards of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares and performance units, as well as cash-based awards. The 2016 Plan is administered by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine which employees will receive awards, the amount of any awards, and other terms and conditions of such awards. Awards granted under the 2016 Plan typically vest over a period of one to four years. The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Stock options $ $ $ $ Restricted stock awards Restricted stock units — — Total stock-based compensation $ $ $ $ Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Costs of product revenue $ $ $ $ Selling, general and administrative Research and development Total stock-based compensation $ $ $ $ Stock-based compensation expense is recognized on a straight-line basis over the underlying requisite service period of the stock-based award. Stock options to purchase the Company’s common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to four years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions for the nine months ended September 30, 2017 and 2016 regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below: 2017 2016 Risk-free interest rates 1.78% - 2.09% 1.23% - 2.05% Expected life 5.56 years 5.75 - 7.02 years Volatility 30.78% - 34.13% 33.57% - 41.60% Expected dividend yield 0.55% - 0.74% 0.0% - 0.73% Stock option activity for the nine months ended September 30, 2017 was as follows: Shares Subject Weighted Weighted Aggregate Outstanding at December 31, 2016 $ Granted Exercised ) Forfeited ) Outstanding at September 30, 2017 $ $ Exercisable at September 30, 2017 $ $ Exercisable and expected to vest at September 30, 2017 (a) $ $ (a) In addition to the options that are vested at September 30, 2017, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of September 30, 2017. (b) The aggregate intrinsic value is based on the positive difference between the fair value of the Company’s common stock price of $29.75 on September 30, 2017 and the exercise price of the underlying stock options. The weighted average fair value of options granted was $7.61 and $9.67 per share for the nine months ended September 30, 2017 and 2016, respectively. The total intrinsic value of options exercised was $10.9 million and $10.4 million for the nine months ended September 30, 2017 and 2016, respectively. Restricted stock award activity for the nine months ended September 30, 2017 was as follows: Shares Subject Weighted Outstanding at December 31, 2016 $ Vested ) Forfeited ) Outstanding at September 30, 2017 $ The total fair value of restricted stock vested was $1.5 million and $1.4 million in each of the nine months ended September 30, 2017 and 2016. Restricted stock unit activity for the nine months ended September 30, 2017 was as follows: Shares Subject Weighted Outstanding at December 31, 2016 $ Granted Vested ) Forfeited ) Outstanding at September 30, 2017 $ The total fair value of restricted stock units vested was $0.2 million in the nine months ended September 30, 2017, with no corresponding amount in the comparable period in 2016. At September 30, 2017, the Company expects to recognize pre-tax stock-based compensation expense of $10.0 million associated with outstanding stock option awards granted under the Company’s stock plans over the weighted average remaining service period of 2.35 years. The Company expects to recognize additional pre-tax stock-based compensation expense of $1.4 million associated with outstanding restricted stock awards granted under the Company’s stock plans over the weighted average remaining service period of 1.63 years. The Company also expects to recognize additional pre-tax stock-based compensation expense of $14.5 million associated with outstanding restricted stock units granted under the 2016 Plan over the weighted average remaining service period of 3.57 years. In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation - Improvements to Employee Share-Based Payment Accounting . The new standard simplifies accounting for share-based payment transactions, including income tax consequences and the classification of the tax impact on the statement of cash flows. The Company adopted this standard effective January 1, 2017. The ASU requires that the difference between the actual tax benefit realized upon exercise or vesting, as applicable, and the tax benefit recorded based on the fair value of the stock award at the time of grant (the “excess tax benefits”) be reflected as a reduction of the current period provision for income taxes with any shortfall recorded as an increase in the tax provision rather than as a component of changes to additional paid-in capital. The ASU also requires the excess tax benefit realized be reflected as an operating cash flow rather than a financing cash flow. This standard was adopted by the Company on a modified retrospective basis, which resulted in a cumulative adjustment to retained earnings of $3.6 million related to the timing of when excess tax benefits are recognized. The actual benefit realized in future periods is inherently uncertain and will vary based on the timing and relative value realized for future share-based transactions. The Company continues to utilize a historical forfeiture rate to estimate future forfeitures. |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Sep. 30, 2017 | |
Earnings Per Share | |
Earnings Per Share | 4. Earnings Per Share Net income per common share attributable to Bruker Corporation shareholders is calculated by dividing net income attributable to Bruker Corporation by the weighted-average shares outstanding during the period. The diluted net income per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options and the vesting of restricted stock, reduced by the number of shares which are assumed to be purchased by the Company under the treasury stock method. The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker Corporation shareholders (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income attributable to Bruker Corporation, as reported $ $ $ $ Weighted average shares outstanding: Weighted average shares outstanding-basic Effect of dilutive securities: Stock options and restricted stock Net income per common share attributable to Bruker Corporation shareholders: Basic $ $ $ $ Diluted $ $ $ $ Stock options to purchase approximately 1.0 million shares and 2.4 million shares were excluded from the computation of diluted earnings per share in the three months ended September 30, 2017 and 2016, respectively, as their effect would have been anti-dilutive. Approximately 1.7 million shares and 1.9 million shares were excluded from the computation of diluted earnings per share in the nine months ended September 30, 2017 and 2016, respectively, as their effect would have been anti-dilutive. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 9 Months Ended |
Sep. 30, 2017 | |
Fair Value of Financial Instruments | |
Fair Value of Financial Instruments | 5. Fair Value of Financial Instruments The Company applies the following hierarchy to determine the fair value of financial instruments, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The levels in the hierarchy are defined as follows: Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The valuation techniques that may be used by the Company to determine the fair value of Level 2 and Level 3 financial instruments are the market approach, the income approach and the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value based on current market expectations about those future amounts, including present value techniques, option-pricing models and the excess earnings method. The cost approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The following tables set forth the Company’s financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at September 30, 2017 and December 31, 2016 (in millions): September 30, 2017 Total Quoted Prices Significant Significant Assets: Embedded derivatives in purchase and delivery contracts $ $ — $ $ — Foreign exchange contracts — — Fixed price commodity contracts — — Total assets recorded at fair value $ $ — $ $ — Liabilities: Contingent consideration $ $ — $ — $ Foreign exchange contracts — — Embedded derivatives in purchase and delivery contracts — — Total liabilities recorded at fair value $ $ — $ $ December 31, 2016 Total Quoted Prices Significant Significant Assets: Embedded derivatives in purchase and delivery contracts $ $ — $ $ — Fixed price commodity contracts — — Total assets recorded at fair value $ $ — $ $ — Liabilities: Contingent consideration $ $ — $ — $ Foreign exchange contracts — — Embedded derivatives in purchase and delivery contracts — — Total liabilities recorded at fair value $ $ — $ $ The Company’s financial instruments consist primarily of cash equivalents, short-term investments, restricted cash, derivative instruments consisting of forward foreign exchange contracts, commodity contracts, derivatives embedded in certain purchase and sale contracts, accounts receivable, borrowings under a revolving credit agreement, accounts payable, contingent consideration and long-term debt. The carrying amounts of the Company’s cash equivalents, short-term investments and restricted cash, accounts receivable, borrowings under a revolving credit agreement and accounts payable approximate fair value because of their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company’s long-term debt consists principally of a private placement arrangement entered into in 2012 with various fixed interest rates based on the maturity date. The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was $230.3 million and $253.3 million at September 30, 2017 and December 31, 2016, respectively, based on the outstanding amount at September 30, 2017 and December 31, 2016, market prices and observable sources with similar maturity dates. The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the three or nine months ended September 30, 2017 or 2016. Excluded from the table above are cash equivalents, restricted cash and short-term investments related to time and call deposits. The Company has a program to enter into time deposits with varying maturity dates ranging from one to twelve months, as well as call deposits for which the Company has the ability to redeem the invested amounts over a period of 95 days. The Company has classified these investments within cash and cash equivalents or short-term investments within the consolidated balance sheets based on call and maturity dates and these are not subject to fair value measurement. There are no cash equivalents, $3.8 million and $3.5 million of restricted cash and $165.3 million and $157.9 million of short-term investments outstanding as of September 30, 2017 and December 31, 2016, respectively. As part of certain acquisitions in 2017, 2016, and 2015, the Company recorded contingent consideration liabilities that have been classified as Level 3 in the fair value hierarchy. The contingent consideration represents the estimated fair value of future payments to the former shareholders of applicable acquired companies based on achieving annual revenue and gross margin targets in certain years as specified in the purchase and sale agreements. The Company initially values the contingent considerations by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term. For the nine months ended September 30, 2017, additional contingent consideration of $2.0 million was recognized in earnings related to a recent acquisition within the Bruker Nano Group based upon an increase in forecasted revenue levels for the acquired business for the remainder of 2017 and was recorded within other charges, net in the unaudited condensed consolidated statements of income and comprehensive income. The following table sets forth the changes in contingent consideration liabilities for the nine months ended September 30, 2017 (in millions): Balance at December 31, 2016 $ Current period additions Current period adjustments Current period settlements ) Foreign currency effect Balance at September 30, 2017 $ |
Inventories
Inventories | 9 Months Ended |
Sep. 30, 2017 | |
Inventories | |
Inventories | 6. Inventories Inventories consisted of the following (in millions): September 30, December 31, 2017 2016 Raw materials $ $ Work-in-process Finished goods Demonstration units Inventories $ $ Finished goods include in-transit systems that have been shipped to the Company’s customers, but not yet installed and accepted by the customer. As of September 30, 2017 and December 31, 2016, the value of inventory-in-transit was $44.1 million and $37.5 million, respectively. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory . This guidance eliminates the measurement of inventory at market value, and inventory will now be measured at the lower of cost and net realizable value. The ASU defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. No other changes were made to the current guidance on inventory measurement. The Company adopted ASU No. 2015-11 on a prospective basis in the first quarter of 2017. The adoption did not have a material impact on the Company’s unaudited condensed consolidated financial statements. |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets | 9 Months Ended |
Sep. 30, 2017 | |
Goodwill and Other Intangible Assets | |
Goodwill and Other Intangible Assets | 7. Goodwill and Other Intangible Assets The following table sets forth the changes in the carrying amount of goodwill for the nine months ended September 30, 2017 (in millions): Balance at December 31, 2016 $ Goodwill acquired during the period Foreign currency effect Balance at September 30, 2017 $ The following is a summary of intangible assets (in millions): September 30, 2017 December 31, 2016 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Existing technology and related patents $ $ ) $ $ $ ) $ Customer relationships ) ) Non compete contracts ) ) Trade names ) ) Intangible assets subject to amortization ) ) In-process research and development — — Intangible assets $ $ ) $ $ $ ) $ For the three months ended September 30, 2017 and 2016, the Company recorded amortization expense of $8.2 million and $5.4 million, respectively, related to intangible assets subject to amortization. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization expense of $22.6 million and $16.2 million, respectively, related to intangible assets subject to amortization. The goodwill and intangible assets acquired in the nine months ended September 30, 2017 related primarily to the Hysitron and Luxendo acquisitions. Please see Note 2—Acquisitions, for additional details on the goodwill and intangibles acquired. |
Debt
Debt | 9 Months Ended |
Sep. 30, 2017 | |
Debt | |
Debt | 8. Debt The Company’s debt obligations as of September 30, 2017 and December 31, 2016 consisted of the following (in millions): September 30, December 31, 2017 2016 US Dollar revolving loan under the 2015 Credit Agreement $ $ US Dollar notes under the Note Purchase Agreement Unamortized debt issuance costs under the Note Purchase Agreement ) ) Capital lease obligations and other loans Total debt Current portion of long-term debt — ) Total long-term debt, less current portion $ $ On October 27, 2015, the Company entered into a new revolving credit agreement, referred to as the 2015 Credit Agreement. The 2015 Credit Agreement provides a maximum commitment on the Company’s revolving credit line of $500 million and a maturity date of October 2020. Borrowings under the revolving credit line of the 2015 Credit Agreement accrue interest, at the Company’s option, at either (a) the greatest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) adjusted LIBOR plus 1.00%, plus margins ranging from 0.00% to 0.30% or (b) LIBOR, plus margins ranging from 0.90% to 1.30%. There is also a facility fee ranging from 0.10% to 0.20%. Borrowings under the 2015 Credit Agreement are secured by guarantees from certain material subsidiaries, as defined in the 2015 Credit Agreement. The 2015 Credit Agreement also requires the Company to maintain certain financial ratios related to maximum leverage and minimum interest coverage (as defined in the 2015 Credit Agreement). Specifically, the Company’s leverage ratio cannot exceed 3.5 and the Company’s interest coverage ratio cannot be less than 2.5. In addition to the financial ratios, the 2015 Credit Agreement contains negative covenants, including among others, restrictions on liens, indebtedness of the Company and its subsidiaries, asset sales, dividends and transactions with affiliates. Failure to comply with any of these restrictions or covenants may result in an event of default on the 2015 Credit Agreement, which could permit acceleration of the debt and require the Company to prepay the debt before its scheduled due date. The following is a summary of the maximum commitments and the net amounts available to the Company under the 2015 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at September 30, 2017 (in millions): Weighted Total Amount Outstanding Outstanding Total Amount 2015 Credit Agreement % $ $ $ $ Other lines of credit — — Total revolving lines of credit $ $ $ $ In January 2012, the Company entered into a note purchase agreement, referred to as the Note Purchase Agreement, with a group of accredited institutional investors. Pursuant to the Note Purchase Agreement, the Company issued and sold $240.0 million of senior notes, referred to as the Senior Notes, which consisted of the following: · $20.0 million 3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017; · $15.0 million 3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019; · $105.0 million 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022; and · $100.0 million 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024. On January 18, 2017, the outstanding $20.0 million principal amount of Tranche A of the Senior Notes was repaid in accordance with the terms of the Note Purchase Agreement. Under the terms of the Note Purchase Agreement, the Company may issue and sell additional senior notes up to an aggregate principal amount of $600 million, subject to certain conditions. Interest on the Senior Notes is payable semi-annually on January 18 and July 18 of each year. The Senior Notes are unsecured obligations of the Company and are fully and unconditionally guaranteed by certain of the Company’s direct and indirect subsidiaries. The Senior Notes rank pari passu in right of repayment with the Company’s other senior unsecured indebtedness. The Company may prepay some or all of the Senior Notes at any time in an amount not less than 10% of the original aggregate principal amount of the Senior Notes to be prepaid, at a price equal to the sum of (a) 100% of the principal amount thereof, plus accrued and unpaid interest, and (b) the applicable make-whole amount, upon not less than 30 and no more than 60 days written notice to the holders of the Senior Notes. In the event of a change in control of the Company, as defined in the Note Purchase Agreement, the Company may be required to prepay the Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest. The Note Purchase Agreement contains affirmative covenants, including, without limitation, maintenance of corporate existence, compliance with laws, maintenance of insurance and properties, payment of taxes, addition of subsidiary guarantors and furnishing notices and other information. The Note Purchase Agreement also contains certain restrictive covenants that restrict the Company’s ability to, among other things, incur liens, transfer or sell assets, engage in certain mergers and consolidations and enter into transactions with affiliates. The Note Purchase Agreement also includes customary representations and warranties and events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding Senior Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of Senior Notes affected thereby may declare all Senior Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the Senior Notes may declare all the Senior Notes to be due and payable immediately. Pursuant to the Note Purchase Agreement, so long as any Senior Notes are outstanding the Company will not permit (i) its leverage ratio, as determined pursuant to the Note Purchase Agreement, as of the end of any fiscal quarter to exceed 3.50 to 1.00, (ii) its interest coverage ratio as determined pursuant to the Note Purchase Agreement as of the end of any fiscal quarter for any period of four consecutive fiscal quarters to be less than 2.50 to 1 or (iii) priority debt at any time to exceed 25% of consolidated net worth, as determined pursuant to the Note Purchase Agreement. As of September 30, 2017, the Company was in compliance with the covenants of the Note Purchase Agreement and the 2015 Credit Agreement. The Company’s leverage ratio (as defined in the respective agreements) was 1.61 and interest coverage ratio (as defined in the respective agreements) was 14.8. |
Derivative Instruments and Hedg
Derivative Instruments and Hedging Activities | 9 Months Ended |
Sep. 30, 2017 | |
Derivative Instruments and Hedging Activities | |
Derivative Instruments and Hedging Activities | 9. Derivative Instruments and Hedging Activities Interest Rate Risks The Company’s exposure to interest rate risk relates primarily to outstanding variable rate debt and adverse movements in the related short-term market rates. The most significant component of the Company’s interest rate risk relates to amounts outstanding under the 2015 Credit Agreement, which totaled $260.0 million at September 30, 2017. The Company currently has approximately equal levels of fixed and floating rate debt, which limits the exposure to adverse movements in interest rates. Foreign Exchange Rate Risk Management The Company generates a substantial portion of its revenues and expenses in international markets, principally Germany and other countries in the European Union and Switzerland, which subjects its operations to the exposure of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company periodically enters into foreign currency contracts in order to minimize the volatility that fluctuations in currency translation have on its monetary transactions. Under these arrangements, the Company typically agrees to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates with maturities of less than twelve months. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the consolidated statements of income and comprehensive income. The Company had the following notional amounts outstanding under foreign exchange contracts at September 30, 2017 and December 31, 2016 (in millions): Buy Notional Sell Maturity Notional Fair Value of Fair Value of September 30, 2017: Euro U.S. Dollars October 2017 to $ $ $ — U.S. Dollars Euro October 2017 — Swiss Francs U.S. Dollars October 2017 — Euro Polish Zloty October 2017 — — $ $ $ December 31, 2016: Euro U.S. Dollars January 2017 $ $ — $ Swiss Francs U.S. Dollars January 2017 — U.S. Dollars Israel Shekel January 2017 — — Israel Shekel U.S. Dollars January 2017 — — Euro Polish Zloty January 2017 — — $ $ — $ In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $90.4 million for the delivery of products and $2.4 million for the purchase of products at September 30, 2017 and $120.7 million for the delivery of products and $2.3 million for the purchase of products at December 31, 2016. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the consolidated statements of income and comprehensive income. Commodity Price Risk Management The Company has arrangements with certain customers under which it has a firm commitment to deliver copper based superconductor wire at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company’s sales of these commodities, the Company enters into commodity hedge contracts. At September 30, 2017 and December 31, 2016, the Company had fixed price commodity contracts with notional amounts aggregating $4.7 million and $2.7 million, respectively. The changes in the fair value of these commodity contracts are recorded within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. The fair value of the derivative instruments described above is recorded in the unaudited condensed consolidated balance sheets for the periods as follows (in millions): September 30, December 31, Balance Sheet Location 2017 2016 Derivative assets: Foreign exchange contracts Other current assets $ $ — Embedded derivatives in purchase and delivery contracts Other current assets Fixed price commodity contracts Other current assets Embedded derivatives in purchase and delivery contracts Other long-term assets — Derivative liabilities: Foreign exchange contracts Other current liabilities $ $ Embedded derivatives in purchase and delivery contracts Other current liabilities Embedded derivatives in purchase and delivery contracts Other long-term liabilities — The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Foreign exchange contracts $ ) $ $ $ Embedded derivatives in purchase and delivery contracts ) ) — Fixed price commodity contracts — Net impact to interest and other income (expense) $ ) $ $ $ The amounts related to derivative instruments not designated as hedging instruments are recorded within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. |
Provision for Income Taxes
Provision for Income Taxes | 9 Months Ended |
Sep. 30, 2017 | |
Provision for Income Taxes | |
Provision for Income Taxes | 10. Provision for Income Taxes The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold. The income tax provision for the three months ended September 30, 2017 and 2016 was $9.8 million and $(4.0) million, respectively, representing effective tax rates of 20.7% and (9.3)%, respectively. The income tax provision for the nine months ended September 30, 2017 and 2016 was $25.9 million and $3.8 million, respectively, representing effective tax rates of 23.7% and 4.3%, respectively. The increase in the Company’s effective tax rate for the three and nine months ended September 30, 2017, compared to the same periods in 2016, was primarily caused by the release of valuation allowances in the first nine months of 2016. The effective tax rate in the nine months ended September 30, 2016 was also favorably impacted by the recognition of previously uncertain tax benefits due to the closure of certain tax audits. The Company’s effective tax rate may change over time as the amount or mix of income and taxes changes among the jurisdictions in which the Company is subject to tax. As of September 30, 2017 and December 31, 2016, the Company had unrecognized tax benefits, excluding penalties and interest, of approximately $6.1 million and $6.2 million, respectively, of which $5.2 million and $5.3 million, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of September 30, 2017 and December 31, 2016, approximately $0.5 million of accrued interest and penalties related to uncertain tax positions was included in each period in other long-term liabilities on the unaudited condensed consolidated balance sheets. Penalties and interest related to unrecognized tax benefits of $0.9 million and $1.5 million were recorded in the provision for income taxes during the three and nine months ended September 30, 2016, respectively. No corresponding amount was recorded in the three and nine month periods ended September 30, 2017. The Company files tax returns in the United States, which includes federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The majority of the Company’s earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 2017 are expected to be 28.0% and 20.5% for Germany and Switzerland, respectively. The expected mix of earnings in those two jurisdictions results in an expected reduction of 8.8% from the US statutory rate of 35.0% in 2017. The Company has not been party to any tax holiday agreements. The tax years 2013 to 2016 are open to examination in Germany and Switzerland. In 2016, the Company settled tax audits in Germany and Switzerland. The settlements were immaterial to the consolidated financial statements. Tax years 2011 to 2016 remain open for examination in the United States. The Company asserts that its foreign earnings, with the exception of its foreign earnings that have been previously taxed by the U.S., are indefinitely reinvested. The Company regularly evaluates its assertion that its foreign earnings are indefinitely reinvested. If the cash, cash equivalents and short-term investments held by the Company’s foreign subsidiaries are needed to fund operations in the United States or the Company otherwise elects to repatriate the unremitted earnings of its foreign subsidiaries in the form of dividends or otherwise, or if the shares of the subsidiaries were sold or transferred, the Company would likely be subject to additional U.S. income taxes, net of the impact of any available tax credits, which could result in a higher effective tax rate in the future. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2017 | |
Commitments and Contingencies | |
Commitments and Contingencies | 11. Commitments and Contingencies In accordance with Accounting Standards Codification (ASC) Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages, or other costs to the extent specific losses are probable and estimable. Litigation and Related Contingencies Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. The Company believes the outcome of pending proceedings, individually and in the aggregate, will not have a material impact on the Company’s financial statements. As of September 30, 2017 and December 31, 2016, no material accruals have been recorded for potential contingencies. Governmental Investigations The Company is subject from time to time to investigations by U.S. or foreign governmental agencies, from which civil, criminal or administrative proceedings could result. The Korea Fair Trade Commission (“KFTC”) has conducted an investigation into improper bidding by Bruker Korea Co., Ltd. and several other companies in connection with bids for sales of X-ray systems in 2010 and 2012. Three of the bids under investigation involved Bruker Korea. The Company cooperated fully with the KFTC regarding this matter. In September 2016, the KFTC fined Bruker Korea approximately $15,000 and referred the matter to the Korean Public Prosecutor’s Office (“PPO”) for criminal prosecution. On May 31, 2017, the PPO issued official notice of its decision not to pursue criminal proceedings against Bruker Korea. Additionally, since December 2016, various Korean governmental entities imposed suspensions on Bruker Korea, with overlapping suspension periods ranging from three to six months. During the periods of these suspensions, Bruker Korea was prohibited from bidding for or conducting sales to Korean governmental agencies. Sales to these customers were less than 1% of the Company’s revenue for the year ended December 31, 2016. At September 30, 2017, all such suspension periods have lapsed. The Company considers these matters resolved and no additional payments are owed or accrued as of September 30, 2017 in connection with such resolutions. Letters of Credit and Guarantees At September 30, 2017 and December 31, 2016, the Company had bank guarantees of $124.0 million and $131.5 million, respectively, related primarily to customer advances. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered or warranty obligations are not fulfilled in compliance with the terms of the contract. These guarantees affect the availability of the Company’s lines of credit. |
Shareholders' Equity
Shareholders' Equity | 9 Months Ended |
Sep. 30, 2017 | |
Shareholders' Equity | |
Shareholders' Equity | 12. Shareholders’ Equity Share Repurchase Program In May 2017, the Company’s Board of Directors approved a share repurchase program under which repurchases of common stock up to $225.0 million may occur from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, legal requirements and other considerations. A total of 3,063,133 shares were repurchased at an aggregate cost of $87.9 million in the three months ended September 30, 2017 and 4,658,063 shares were repurchased at an aggregate cost of $131.8 million in the nine months ended September 30, 2017. Any future repurchases will be funded from cash on hand, future cash flows from operations and available borrowings under the revolving credit facility. The repurchased shares are reflected within Treasury stock in the accompanying unaudited condensed consolidated balance sheet at September 30, 2017. Subsequent to September 30, 2017 through November 6, 2017, the Company has repurchased an additional 660,000 shares at an aggregate cost of $20.4 million. Cash Dividends on Shares of Common Stock On February 22, 2016, the Company announced the establishment of a dividend policy and the declaration by its Board of Directors of an initial quarterly cash dividend in the amount of $0.04 per share of the Company’s issued and outstanding common stock. Under the dividend policy, the Company will target a cash dividend to the Company’s shareholders in the amount of $0.16 per share per annum, payable in equal quarterly installments. Dividends were paid on March 24, 2017 to shareholders of record as of March 8, 2017 and on June 23, 2017 to shareholders of record as of June 5, 2017, in each case for an aggregate cost of $6.4 million and on September 22, 2017 to shareholders of record as of September 5, 2017 for an aggregate cost of $6.3 million. Subsequent dividend declarations and the establishment of record and payment dates for such future dividend payments, if any, are subject to the Board of Directors’ continuing determination that the dividend policy is in the best interests of the Company’s shareholders. The dividend policy may be suspended or cancelled at the discretion of the Board of Directors at any time. Accumulated Other Comprehensive Income Comprehensive income refers to revenues, expenses, gains and losses that under U.S. GAAP are included in other comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity, net of tax. The Company’s other comprehensive income is composed primarily of foreign currency translation adjustments and changes in the funded status of defined benefit pension plans. The following is a summary of comprehensive income (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Consolidated net income $ $ $ $ Foreign currency translation adjustments Pension liability adjustments, net of tax — Net comprehensive income Less: Comprehensive income attributable to noncontrolling interests Comprehensive income attributable to Bruker Corporation $ $ $ $ The following is a summary of the components of accumulated other comprehensive income (loss), net of tax, at September 30, 2017 (in millions): Foreign Pension Accumulated Balance at December 31, 2016 $ ) $ ) $ ) Other comprehensive income (loss) before reclassifications ) Amounts reclassified from other comprehensive income (loss), net of tax of $0.4 million — Net current period other comprehensive income — Balance at September 30, 2017 $ $ ) $ |
Noncontrolling Interests
Noncontrolling Interests | 9 Months Ended |
Sep. 30, 2017 | |
Noncontrolling Interests | |
Noncontrolling Interests | 13. Noncontrolling Interests Noncontrolling interests represent the minority shareholders’ proportionate share of the Company’s majority owned subsidiaries. The following table sets forth the changes in noncontrolling interests (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Balance at beginning of period $ $ $ $ Net income Foreign currency translation adjustments Cash payments to noncontrolling interests — ) ) ) Balance at end of period $ $ $ $ |
Other Charges, Net
Other Charges, Net | 9 Months Ended |
Sep. 30, 2017 | |
Other Charges, Net | |
Other Charges, Net | 14. Other Charges, Net The components of other charges, net were as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Information technology transformation costs $ $ $ $ Restructuring charges Acquisition-related charges Other — — Other charges, net $ $ $ $ Restructuring Initiatives 2016 The Company commenced a restructuring initiative in the third quarter of 2016 to address lower demand in the Bruker CALID and Bruker Nano Groups as a result of softness in order entry levels from European academic institutions and ongoing weakness in several of the industrial end market segments served by the Bruker Nano Group. This initiative was intended to improve the Bruker CALID Group and Bruker Nano Group operating results in response to these market conditions. Restructuring actions resulted in a reduction of approximately 125 employees within the Bruker CALID and Bruker Nano Groups. The following is a summary of the restructuring expenses related to this initiative which are recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income for the three and nine months ended September 30, 2017 and 2016: Three months ended September 30, Nine months ended September 30, Three and Nine months ended September 30, 2017 2017 2016 Severance and Inventory Total Severance and Inventory Total Severance and Inventory Total Cost of revenues $ $ $ $ $ $ $ $ $ Other charges, net — — $ $ $ $ $ $ $ $ $ Total restructuring and other one-time charges incurred through September 30, 2017 related to this initiative were $16.3 million, of which $13.2 million related to employee separation and facility exit costs and $3.1 million related to estimated inventory write-downs and asset impairments. Total restructuring and other one-time charges related to this initiative in 2016 and 2017 are expected to be between $17.0 and $19.0 million, of which $16.0 to $17.5 million relate to employee separation and facility exit costs and $1.0 to $1.5 million relate to estimated inventory write-downs and asset impairments. 2015 The Company commenced a restructuring initiative in 2015 within the Bruker BioSpin Group, which was developed as a result of a revenue decline that occurred during the second half of 2014 and continued during the first half of 2015. This initiative was intended to improve Bruker BioSpin Group’s operating results. Restructuring actions resulted in a reduction of employee headcount within the Bruker BioSpin Group of approximately 9%. The expenses and gain related to the sale of a manufacturing facility in connection with this initiative were incurred in the nine months ended September 30, 2017. The following is a summary of the restructuring expenses related to this initiative which are recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income for the nine months ended September 30, 2017 and 2016, respectively: Nine months ended September 30, 2017 2016 Severance and Inventory Total Severance and Inventory Total Cost of revenues $ ) $ — $ ) $ $ — $ Other charges, net — — — — $ ) $ — $ ) $ $ — $ As of September 30, 2017, expenses incurred under this restructuring initiative were substantially complete. There were no restructuring expenses incurred for this program in the three months ended September 30, 2017 or 2016. Other Programs Restructuring charges for the three and nine month periods ended September 30, 2017 and 2016 included charges for various other programs which were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Cost of revenues $ $ $ $ Other charges, net $ $ $ $ The following table sets forth the changes in restructuring reserves for the nine months ended September 30, 2017 (in millions): Total Severance Exit Costs Provisions Balance at December 31, 2016 $ $ $ $ Restructuring charges Cash payments ) ) ) ) Other, non-cash adjustments and foreign currency effect ) ) ) ) Balance at September 30, 2017 $ $ $ $ |
Interest and Other Income (Expe
Interest and Other Income (Expense), Net | 9 Months Ended |
Sep. 30, 2017 | |
Interest and Other Income (Expense), Net | |
Interest and Other Income (Expense), Net | 15. Interest and Other Income (Expense), Net The components of interest and other income (expense), net, were as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Interest expense, net $ ) $ ) $ ) $ ) Exchange gains (losses) on foreign currency transactions — ) ) Other ) Interest and other income (expense), net $ ) $ ) $ ) $ ) |
Business Segment Information
Business Segment Information | 9 Months Ended |
Sep. 30, 2017 | |
Business Segment Information | |
Business Segment Information | 16. Business Segment Information The Company has two reportable segments, BSI and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements. Revenue and operating income by reportable segment are presented below (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Revenue: BSI $ $ $ $ BEST Eliminations (a) ) ) ) ) Total revenue $ $ $ $ Operating Income BSI $ $ $ $ BEST Corporate, eliminations and other (b) ) Total operating income $ $ $ $ (a) Represents product and service revenue between reportable segments. (b) Represents corporate costs and eliminations not allocated to the reportable segments. Total assets by reportable segment are as follows (in millions): September 30, December 31, 2017 2016 Assets: BSI $ $ BEST Eliminations and other (a) ) ) Total assets $ $ (a) Assets not allocated to the reportable segments and eliminations of intercompany transactions. |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2017 | |
Recent Accounting Pronouncements | |
Recent Accounting Pronouncements | 17. Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Boards (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The new standard simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. While early adoption is permitted, the Company expects to adopt ASU No. 2017-04 as of the effective date. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements upon adoption. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business . This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective as of January 1, 2018. While early adoption is permitted, the Company expects to adopt ASU No. 2017-01 prospectively as of the effective date. The Company is evaluating the provisions of this standard and has not determined what impact the adoption of ASU No. 2017-01 will have on the Company’s consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfer of Assets Other than Inventory . The new standard requires recognition of current and deferred income taxes resulting from an intra-entity transfer of any asset (excluding inventory) when the transfer occurs. This is a change from existing GAAP which prohibits recognition of current and deferred income taxes until the asset is sold to a third party. The new standard is effective as of January 1, 2018. While early adoption is permitted, the Company expects to adopt ASU No. 2016-16 as of the effective date. The Company is evaluating the provisions of this standard and has not determined what impact the adoption of ASU No. 2016-16 will have on the Company’s unaudited condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases . The new standard provides guidance on the recognition, measurement, presentation, and disclosure of leases. The new standard supersedes present U.S. GAAP guidance on leases and requires substantially all leases to be reported on the balance sheet as right-of-use assets and lease liabilities, as well as additional disclosures. The new standard is effective as of January 1, 2019. While early adoption is permitted, the Company expects to adopt ASU No. 2016-02 as of the effective date. The Company is evaluating the provisions of this standard and has not determined what impact the adoption of ASU No. 2016-02 will have on the Company’s unaudited condensed consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers , which supersedes the revenue recognition requirements under Accounting Standards Codification (ASC) Topic 605. The new guidance was the result of a joint project between the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and to develop common revenue standards for U.S. GAAP and International Financial Reporting Standards. The core principle of the new guidance is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No. 2014-09 was originally effective prospectively for annual periods beginning after December 15, 2016, and interim periods within those years. In August 2015, the FASB elected to defer the effective date of ASU No. 2014-09 by one year to annual periods beginning after December 15, 2017, with early application permitted as of the original effective date. The new guidance may be applied on a retrospective basis for all prior periods presented, or on a modified retrospective basis with the cumulative effect of the new guidance as of the date of initial application. The new guidance will be effective for the Company as of January 1, 2018 and the Company currently intends to use the modified retrospective transition method. The Company substantially completed the impact assessment phase of its evaluation of ASU No. 2014-09. Under the new guidance, there are specific criteria to determine if a performance obligation should be recognized over time or at a point in time. Accordingly, the Company has identified certain project-based orders in the BEST Segment and CBRNE detection orders in the Bruker CALID Group for which the timing of when the Company recognizes revenue may be impacted. Due to the complexity of these project-based orders, revenue recognition under the new standard is highly dependent on specific contract terms. The Company continues to assess the impact of the new standard, but based on preliminary analysis does not expect the adoption of ASU No. 2014-09 to be material to the consolidated financial statements. The Company also expects to implement additional processes and controls, as well as additional disclosures to comply with the new standard. |
Description of Business (Tables
Description of Business (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Description of Business | |
Schedule of increase in cash flow statement balances due to inclusion of restricted stock | The inclusion of restricted cash increased the balances of the unaudited condensed consolidated statement of cash flows as follows: Nine Months Ended September 30, 2017 2016 Beginning Balance $ $ Ending Balance |
Acquisitions (Tables)
Acquisitions (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Luxendo | |
Acquisitions | |
Components and fair value allocation of the consideration transferred in connection with acquisitions | The components and fair value allocation of the consideration transferred in connection with the acquisition were as follows (in millions): Consideration Transferred: Cash paid $ Cash acquired ) Contingent consideration Total consideration transferred $ Allocation of Consideration Transferred: Inventories Other current and non-current assets Property, plant and equipment Intangible assets: Existing technology Trade name Goodwill Deferred taxes, net ) Liabilities assumed ) Total consideration transferred $ |
Hysitron, Inc | |
Acquisitions | |
Components and fair value allocation of the consideration transferred in connection with acquisitions | The components and fair value allocation of the consideration transferred in connection with the acquisition of Hysitron were as follows (in millions): Consideration Transferred: Cash paid $ Cash acquired ) Contingent consideration Total consideration transferred $ Allocation of Consideration Transferred: Accounts receivable, net $ Inventories Other current assets Property, plant and equipment Intangible assets: Customer relationships Existing technology Trade name Other Goodwill Deferred taxes, net ) Capital lease ) Liabilities assumed ) Total consideration transferred $ |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Stock-Based Compensation | |
Stock-based compensation expense, by award | The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Stock options $ $ $ $ Restricted stock awards Restricted stock units — — Total stock-based compensation $ $ $ $ |
Stock-based compensation expense, cost allocation | The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Costs of product revenue $ $ $ $ Selling, general and administrative Research and development Total stock-based compensation $ $ $ $ |
Assumptions regarding volatility, expected life, dividend yield and risk-free interest rates | Assumptions for the nine months ended September 30, 2017 and 2016 regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below: 2017 2016 Risk-free interest rates 1.78% - 2.09% 1.23% - 2.05% Expected life 5.56 years 5.75 - 7.02 years Volatility 30.78% - 34.13% 33.57% - 41.60% Expected dividend yield 0.55% - 0.74% 0.0% - 0.73% |
Schedule of stock option activity | Stock option activity for the nine months ended September 30, 2017 was as follows: Shares Subject Weighted Weighted Aggregate Outstanding at December 31, 2016 $ Granted Exercised ) Forfeited ) Outstanding at September 30, 2017 $ $ Exercisable at September 30, 2017 $ $ Exercisable and expected to vest at September 30, 2017 (a) $ $ (a) In addition to the options that are vested at September 30, 2017, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of September 30, 2017. (b) The aggregate intrinsic value is based on the positive difference between the fair value of the Company’s common stock price of $29.75 on September 30, 2017 and the exercise price of the underlying stock options. |
Restricted stock awards | |
Stock-Based Compensation | |
Schedule of restricted stock award and restricted stock unit activity | Restricted stock award activity for the nine months ended September 30, 2017 was as follows: Shares Subject Weighted Outstanding at December 31, 2016 $ Vested ) Forfeited ) Outstanding at September 30, 2017 $ |
Restricted stock units | |
Stock-Based Compensation | |
Schedule of restricted stock award and restricted stock unit activity | Restricted stock unit activity for the nine months ended September 30, 2017 was as follows: Shares Subject Weighted Outstanding at December 31, 2016 $ Granted Vested ) Forfeited ) Outstanding at September 30, 2017 $ |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Earnings Per Share | |
Computation of basic and diluted weighted average shares outstanding and net income per common share | The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker Corporation shareholders (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income attributable to Bruker Corporation, as reported $ $ $ $ Weighted average shares outstanding: Weighted average shares outstanding-basic Effect of dilutive securities: Stock options and restricted stock Net income per common share attributable to Bruker Corporation shareholders: Basic $ $ $ $ Diluted $ $ $ $ |
Fair Value of Financial Instr27
Fair Value of Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Fair Value of Financial Instruments | |
Schedule of financial instruments measured at fair value on a recurring basis | The following tables set forth the Company’s financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at September 30, 2017 and December 31, 2016 (in millions): September 30, 2017 Total Quoted Prices Significant Significant Assets: Embedded derivatives in purchase and delivery contracts $ $ — $ $ — Foreign exchange contracts — — Fixed price commodity contracts — — Total assets recorded at fair value $ $ — $ $ — Liabilities: Contingent consideration $ $ — $ — $ Foreign exchange contracts — — Embedded derivatives in purchase and delivery contracts — — Total liabilities recorded at fair value $ $ — $ $ December 31, 2016 Total Quoted Prices Significant Significant Assets: Embedded derivatives in purchase and delivery contracts $ $ — $ $ — Fixed price commodity contracts — — Total assets recorded at fair value $ $ — $ $ — Liabilities: Contingent consideration $ $ — $ — $ Foreign exchange contracts — — Embedded derivatives in purchase and delivery contracts — — Total liabilities recorded at fair value $ $ — $ $ |
Schedule of changes in contingent consideration liabilities | The following table sets forth the changes in contingent consideration liabilities for the nine months ended September 30, 2017 (in millions): Balance at December 31, 2016 $ Current period additions Current period adjustments Current period settlements ) Foreign currency effect Balance at September 30, 2017 $ |
Inventories (Tables)
Inventories (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Inventories | |
Schedule of inventories | Inventories consisted of the following (in millions): September 30, December 31, 2017 2016 Raw materials $ $ Work-in-process Finished goods Demonstration units Inventories $ $ |
Goodwill and Other Intangible29
Goodwill and Other Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Goodwill and Other Intangible Assets | |
Schedule of changes in the carrying amount of goodwill | The following table sets forth the changes in the carrying amount of goodwill for the nine months ended September 30, 2017 (in millions): Balance at December 31, 2016 $ Goodwill acquired during the period Foreign currency effect Balance at September 30, 2017 $ |
Summary of intangible assets | The following is a summary of intangible assets (in millions): September 30, 2017 December 31, 2016 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Existing technology and related patents $ $ ) $ $ $ ) $ Customer relationships ) ) Non compete contracts ) ) Trade names ) ) Intangible assets subject to amortization ) ) In-process research and development — — Intangible assets $ $ ) $ $ $ ) $ |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Debt | |
Components of debt obligations | The Company’s debt obligations as of September 30, 2017 and December 31, 2016 consisted of the following (in millions): September 30, December 31, 2017 2016 US Dollar revolving loan under the 2015 Credit Agreement $ $ US Dollar notes under the Note Purchase Agreement Unamortized debt issuance costs under the Note Purchase Agreement ) ) Capital lease obligations and other loans Total debt Current portion of long-term debt — ) Total long-term debt, less current portion $ $ |
Summary of maximum commitments and net amounts available under the 2015 Credit Agreement and other lines of credit | The following is a summary of the maximum commitments and the net amounts available to the Company under the 2015 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at September 30, 2017 (in millions): Weighted Total Amount Outstanding Outstanding Total Amount 2015 Credit Agreement % $ $ $ $ Other lines of credit — — Total revolving lines of credit $ $ $ $ |
Derivative Instruments and He31
Derivative Instruments and Hedging Activities (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Derivative Instruments and Hedging Activities | |
Schedule of notional amounts outstanding under foreign exchange contracts | The Company had the following notional amounts outstanding under foreign exchange contracts at September 30, 2017 and December 31, 2016 (in millions): Buy Notional Sell Maturity Notional Fair Value of Fair Value of September 30, 2017: Euro U.S. Dollars October 2017 to $ $ $ — U.S. Dollars Euro October 2017 — Swiss Francs U.S. Dollars October 2017 — Euro Polish Zloty October 2017 — — $ $ $ December 31, 2016: Euro U.S. Dollars January 2017 $ $ — $ Swiss Francs U.S. Dollars January 2017 — U.S. Dollars Israel Shekel January 2017 — — Israel Shekel U.S. Dollars January 2017 — — Euro Polish Zloty January 2017 — — $ $ — $ |
Schedule of fair value and balance sheet location of derivative instruments | The fair value of the derivative instruments described above is recorded in the unaudited condensed consolidated balance sheets for the periods as follows (in millions): September 30, December 31, Balance Sheet Location 2017 2016 Derivative assets: Foreign exchange contracts Other current assets $ $ — Embedded derivatives in purchase and delivery contracts Other current assets Fixed price commodity contracts Other current assets Embedded derivatives in purchase and delivery contracts Other long-term assets — Derivative liabilities: Foreign exchange contracts Other current liabilities $ $ Embedded derivatives in purchase and delivery contracts Other current liabilities Embedded derivatives in purchase and delivery contracts Other long-term liabilities — |
Schedule of impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments | The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Foreign exchange contracts $ ) $ $ $ Embedded derivatives in purchase and delivery contracts ) ) — Fixed price commodity contracts — Net impact to interest and other income (expense) $ ) $ $ $ |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Shareholders' Equity | |
Summary of comprehensive income (loss) | The following is a summary of comprehensive income (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Consolidated net income $ $ $ $ Foreign currency translation adjustments Pension liability adjustments, net of tax — Net comprehensive income Less: Comprehensive income attributable to noncontrolling interests Comprehensive income attributable to Bruker Corporation $ $ $ $ |
Summary of the components of accumulated other comprehensive income (loss), net of tax | The following is a summary of the components of accumulated other comprehensive income (loss), net of tax, at September 30, 2017 (in millions): Foreign Pension Accumulated Balance at December 31, 2016 $ ) $ ) $ ) Other comprehensive income (loss) before reclassifications ) Amounts reclassified from other comprehensive income (loss), net of tax of $0.4 million — Net current period other comprehensive income — Balance at September 30, 2017 $ $ ) $ |
Noncontrolling Interests (Table
Noncontrolling Interests (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Noncontrolling Interests | |
Schedule of changes in noncontrolling interests | Noncontrolling interests represent the minority shareholders’ proportionate share of the Company’s majority owned subsidiaries. The following table sets forth the changes in noncontrolling interests (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Balance at beginning of period $ $ $ $ Net income Foreign currency translation adjustments Cash payments to noncontrolling interests — ) ) ) Balance at end of period $ $ $ $ |
Other Charges, Net (Tables)
Other Charges, Net (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Other Charges, Net | |
Components of other charges, net | The components of other charges, net were as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Information technology transformation costs $ $ $ $ Restructuring charges Acquisition-related charges Other — — Other charges, net $ $ $ $ |
Schedule of changes in the restructuring reserves | The following table sets forth the changes in restructuring reserves for the nine months ended September 30, 2017 (in millions): Total Severance Exit Costs Provisions Balance at December 31, 2016 $ $ $ $ Restructuring charges Cash payments ) ) ) ) Other, non-cash adjustments and foreign currency effect ) ) ) ) Balance at September 30, 2017 $ $ $ $ |
Restructuring initiative within Bruker CALID and Bruker Nano Groups | |
Restructuring charges | |
Summary of restructuring expenses | The following is a summary of the restructuring expenses related to this initiative which are recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income for the three and nine months ended September 30, 2017 and 2016: Three months ended September 30, Nine months ended September 30, Three and Nine months ended September 30, 2017 2017 2016 Severance and Inventory Total Severance and Inventory Total Severance and Inventory Total Cost of revenues $ $ $ $ $ $ $ $ $ Other charges, net — — $ $ $ $ $ $ $ $ $ |
Restructuring initiative within Bruker BioSpin Group | |
Restructuring charges | |
Summary of restructuring expenses | The following is a summary of the restructuring expenses related to this initiative which are recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income for the nine months ended September 30, 2017 and 2016, respectively: Nine months ended September 30, 2017 2016 Severance and Inventory Total Severance and Inventory Total Cost of revenues $ ) $ — $ ) $ $ — $ Other charges, net — — — — $ ) $ — $ ) $ $ — $ |
Other programs | |
Restructuring charges | |
Summary of restructuring expenses | Restructuring charges for the three and nine month periods ended September 30, 2017 and 2016 included charges for various other programs which were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Cost of revenues $ $ $ $ Other charges, net $ $ $ $ |
Interest and Other Income (Ex35
Interest and Other Income (Expense), Net (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Interest and Other Income (Expense), Net | |
Components of interest and other income (expense), net | The components of interest and other income (expense), net, were as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Interest expense, net $ ) $ ) $ ) $ ) Exchange gains (losses) on foreign currency transactions — ) ) Other ) Interest and other income (expense), net $ ) $ ) $ ) $ ) |
Business Segment Information (T
Business Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Business Segment Information | |
Schedule of revenue, operating income and total assets by reportable segment | Revenue and operating income by reportable segment are presented below (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Revenue: BSI $ $ $ $ BEST Eliminations (a) ) ) ) ) Total revenue $ $ $ $ Operating Income BSI $ $ $ $ BEST Corporate, eliminations and other (b) ) Total operating income $ $ $ $ (a) Represents product and service revenue between reportable segments. (b) Represents corporate costs and eliminations not allocated to the reportable segments. Total assets by reportable segment are as follows (in millions): September 30, December 31, 2017 2016 Assets: BSI $ $ BEST Eliminations and other (a) ) ) Total assets $ $ (a) Assets not allocated to the reportable segments and eliminations of intercompany transactions. |
Description of Business - Segme
Description of Business - Segments (Details) - segment | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Description of Business | ||||
Number of reportable segments | 2 | |||
BSI | ||||
Description of Business | ||||
Segment revenue (as a percent) | 89.70% | 91.80% | 89.00% | 92.70% |
Number of operating segments | 3 |
Description of Business - Accou
Description of Business - Accounting Standards Update 2016-18 (Details) - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Dec. 31, 2015 |
Description of Business | ||||
Cash and cash equivalents, including restricted cash | $ 267.8 | $ 345.9 | $ 282.3 | $ 271.2 |
Accounting Standards Update 2016-18 | Early Adoption | ||||
Description of Business | ||||
Cash and cash equivalents, including restricted cash | $ 3.8 | $ 3.5 | $ 3.6 | $ 4.1 |
Acquisitions - Luxendo (Details
Acquisitions - Luxendo (Details) € in Millions, $ in Millions | May 05, 2017EUR (€) | May 05, 2017USD ($) | Sep. 30, 2017USD ($) | Sep. 30, 2016USD ($) | Dec. 31, 2016USD ($) |
Acquisitions | |||||
Purchase price | $ 65.8 | $ 1.2 | |||
Allocation of Consideration Transferred: | |||||
Goodwill | $ 168.6 | $ 130.6 | |||
Luxendo | |||||
Acquisitions | |||||
Ownership percentage acquired | 100.00% | ||||
Purchase price | € 17 | $ 18.8 | |||
Consideration Transferred: | |||||
Cash paid | 20.1 | ||||
Cash acquired | (1.3) | ||||
Contingent consideration | 3.1 | ||||
Total consideration transferred | 21.9 | ||||
Allocation of Consideration Transferred: | |||||
Inventories | 1.1 | ||||
Other current and non-current assets | 0.4 | ||||
Property, plant and equipment | 0.3 | ||||
Goodwill | 11.2 | ||||
Deferred taxes, net | (2.4) | ||||
Liabilities assumed | (0.4) | ||||
Total consideration transferred | 21.9 | ||||
Existing technology | Luxendo | |||||
Allocation of Consideration Transferred: | |||||
Intangible assets | $ 10.9 | ||||
Amortization period for intangible assets acquired | 7 years | 7 years | |||
Trade names | Luxendo | |||||
Allocation of Consideration Transferred: | |||||
Intangible assets | $ 0.8 | ||||
Amortization period for intangible assets acquired | 10 years | 10 years |
Acquisitions - Hysitron (Detail
Acquisitions - Hysitron (Details) - USD ($) $ in Millions | Jan. 23, 2017 | Sep. 30, 2017 | Dec. 31, 2016 |
Allocation of Consideration Transferred: | |||
Goodwill | $ 168.6 | $ 130.6 | |
Hysitron, Inc | |||
Acquisitions | |||
Ownership percentage acquired | 100.00% | ||
Consideration Transferred: | |||
Cash paid | $ 27.9 | ||
Cash acquired | (0.7) | ||
Contingent consideration | 1.6 | ||
Total consideration transferred | 28.8 | ||
Allocation of Consideration Transferred: | |||
Accounts receivable, net | 3 | ||
Inventories | 3.8 | ||
Other current assets | 0.2 | ||
Property, plant and equipment | 0.6 | ||
Goodwill | 16.6 | ||
Deferred taxes, net | (4.1) | ||
Capital lease | (0.2) | ||
Liabilities assumed | (3.4) | ||
Total consideration transferred | 28.8 | ||
Maximum potential future payments related to the contingent consideration | 10 | ||
Customer relationships | Hysitron, Inc | |||
Allocation of Consideration Transferred: | |||
Intangible assets | $ 5.8 | ||
Amortization period for intangible assets acquired | 7 years | ||
Existing technology | Hysitron, Inc | |||
Allocation of Consideration Transferred: | |||
Intangible assets | $ 4.7 | ||
Amortization period for intangible assets acquired | 5 years | ||
Trade names | Hysitron, Inc | |||
Allocation of Consideration Transferred: | |||
Intangible assets | $ 1.2 | ||
Amortization period for intangible assets acquired | 7 years | ||
Other | Hysitron, Inc | |||
Allocation of Consideration Transferred: | |||
Intangible assets | $ 0.6 | ||
Amortization period for intangible assets acquired | 7 years |
Stock-Based Compensation - Plan
Stock-Based Compensation - Plan Information and Expense (Details) - USD ($) $ in Millions | May 14, 2010 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 |
Stock-Based Compensation | |||||
Total stock-based compensation | $ 3.1 | $ 2.5 | $ 8.4 | $ 6.8 | |
Cost of revenues | |||||
Stock-Based Compensation | |||||
Total stock-based compensation | 0.5 | 0.4 | 1.3 | 1 | |
Selling, general and administrative | |||||
Stock-Based Compensation | |||||
Total stock-based compensation | 2.1 | 1.7 | 5.8 | 4.8 | |
Research and development | |||||
Stock-Based Compensation | |||||
Total stock-based compensation | $ 0.5 | 0.4 | $ 1.3 | 1 | |
2010 Plan | |||||
Stock-Based Compensation | |||||
Common stock authorized for issuance (in shares) | 8,000,000 | 0 | 0 | ||
2010 Plan | Minimum | |||||
Stock-Based Compensation | |||||
Vesting period | 3 years | ||||
2010 Plan | Maximum | |||||
Stock-Based Compensation | |||||
Vesting period | 5 years | ||||
2016 Plan | |||||
Stock-Based Compensation | |||||
Common stock authorized for issuance (in shares) | 9,500,000 | 9,500,000 | |||
2016 Plan | Minimum | |||||
Stock-Based Compensation | |||||
Vesting period | 1 year | ||||
2016 Plan | Maximum | |||||
Stock-Based Compensation | |||||
Vesting period | 4 years | ||||
Stock options | |||||
Stock-Based Compensation | |||||
Total stock-based compensation | $ 1.8 | 2.1 | $ 5.2 | 5.6 | |
Stock options | Minimum | |||||
Stock-Based Compensation | |||||
Vesting period | 3 years | ||||
Stock options | Maximum | |||||
Stock-Based Compensation | |||||
Vesting period | 4 years | ||||
Restricted stock awards | |||||
Stock-Based Compensation | |||||
Total stock-based compensation | 0.4 | $ 0.4 | $ 1.1 | $ 1.2 | |
Restricted stock units | |||||
Stock-Based Compensation | |||||
Total stock-based compensation | $ 0.9 | $ 2.1 |
Stock-Based Compensation - Assu
Stock-Based Compensation - Assumptions (Details) - Stock options | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Stock-Based Compensation | ||
Risk-free interest rates, minimum (as a percent) | 1.78% | 1.23% |
Risk-free interest rates, maximum (as a percent) | 2.09% | 2.05% |
Expected life | 5 years 6 months 22 days | |
Volatility, minimum (as a percent) | 30.78% | 33.57% |
Volatility, maximum (as a percent) | 34.13% | 41.60% |
Minimum | ||
Stock-Based Compensation | ||
Vesting period | 3 years | |
Expected life | 5 years 9 months | |
Expected dividend yield (as a percent) | 0.55% | 0.00% |
Maximum | ||
Stock-Based Compensation | ||
Vesting period | 4 years | |
Expected life | 7 years 7 days | |
Expected dividend yield (as a percent) | 0.74% | 0.73% |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Millions | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Stock options, Shares Subject to Options | ||
Outstanding at the beginning of the period (in shares) | 4,625,678 | |
Granted (in shares) | 180,677 | |
Exercised (in shares) | (961,651) | |
Forfeited (in shares) | (187,946) | |
Outstanding at the end of the period (in shares) | 3,656,758 | |
Exercisable at the end of the period (in shares) | 1,963,600 | |
Exercisable and expected to vest at the end of the period (in shares) | 3,543,147 | |
Stock options, Weighted Average Option Price | ||
Outstanding at the beginning of the period (in dollars per share) | $ 18.73 | |
Granted (in dollars per share) | 27.97 | |
Exercised (in dollars per share) | 16.15 | |
Forfeited (in dollars per share) | 19.87 | |
Outstanding at the end of the period (in dollars per share) | 19.81 | |
Exercisable at the end of the period (in dollars per share) | 17.55 | |
Exercisable and expected to vest at the end of the period (in dollars per share) | $ 19.72 | |
Stock options, additional information | ||
Weighted Average Remaining Contractual Term, Outstanding | 6 years 4 months 24 days | |
Weighted Average Remaining Contractual Term, Exercisable | 5 years 2 months 12 days | |
Weighted Average Remaining Contractual Term, Exercisable and expected to vest | 6 years 3 months 18 days | |
Aggregate Intrinsic Value, Outstanding | $ 36.4 | |
Aggregate Intrinsic Value, Exercisable | 24 | |
Aggregate Intrinsic Value, Exercisable and expected to vest | $ 35.5 | |
Fair value of the Company's common stock price (in dollars per share) | $ 29.75 | |
Weighted average fair values of options granted (in dollars per share) | $ 7.61 | $ 9.67 |
Intrinsic value of options exercised | $ 10.9 | $ 10.4 |
Stock-Based Compensation - Rest
Stock-Based Compensation - Restricted Stock Award and RSU Activity (Details) - USD ($) $ / shares in Units, $ in Millions | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Restricted stock awards | ||
Restricted stock, Shares Subject to Restriction | ||
Outstanding at the beginning of the period (in shares) | 172,506 | |
Vested (in shares) | (82,924) | |
Forfeited (in shares) | (4,053) | |
Outstanding at the end of the period (in shares) | 85,529 | |
Restricted stock, Weighted Average Grant Date Fair Value | ||
Outstanding at the beginning of the period (in dollars per share) | $ 19.37 | |
Vested (in dollars per share) | 18.17 | |
Forfeited (in dollars per share) | 22.46 | |
Outstanding at the end of the period (in dollars per share) | $ 20.39 | |
Total fair value of shares vested | $ 1.5 | $ 1.4 |
Restricted stock units | ||
Restricted stock, Shares Subject to Restriction | ||
Outstanding at the beginning of the period (in shares) | 262,317 | |
Granted (in shares) | 484,234 | |
Vested (in shares) | (8,692) | |
Forfeited (in shares) | (24,729) | |
Outstanding at the end of the period (in shares) | 713,130 | |
Restricted stock, Weighted Average Grant Date Fair Value | ||
Outstanding at the beginning of the period (in dollars per share) | $ 22.32 | |
Granted (in dollars per share) | 26.46 | |
Vested (in dollars per share) | 22.70 | |
Forfeited (in dollars per share) | 22.51 | |
Outstanding at the end of the period (in dollars per share) | $ 25.08 | |
Total fair value of shares vested | $ 0.2 | $ 0 |
Stock-Based Compensation - Unre
Stock-Based Compensation - Unrecognized Compensation Expense (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Stock options | |
Stock-Based Compensation | |
Expected pre-tax stock-based compensation expense | $ 10 |
Weighted average remaining service period | 2 years 4 months 6 days |
Restricted stock awards | |
Stock-Based Compensation | |
Expected pre-tax stock-based compensation expense | $ 1.4 |
Weighted average remaining service period | 1 year 7 months 17 days |
Restricted stock units | |
Stock-Based Compensation | |
Expected pre-tax stock-based compensation expense | $ 14.5 |
Weighted average remaining service period | 3 years 6 months 26 days |
Stock-Based Compensation - Acco
Stock-Based Compensation - Accounting Standards Update 2016-09 (Details) $ in Millions | Jan. 01, 2017USD ($) |
Accounting Standards Update 2016-09 | Adjustment | |
Stock-Based Compensation | |
Cumulative adjustment to retained earnings | $ 3.6 |
Earnings Per Share - Computatio
Earnings Per Share - Computation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Earnings Per Share | ||||
Net income attributable to Bruker Corporation, as reported -basic | $ 37 | $ 46.5 | $ 82 | $ 84.6 |
Net income attributable to Bruker Corporation, as reported -diluted | $ 37 | $ 46.5 | $ 82 | $ 84.6 |
Weighted average shares outstanding: | ||||
Weighted average shares outstanding-basic | 157.5 | 160.8 | 158.9 | 161.8 |
Effect of dilutive securities: | ||||
Stock options and restricted stock (in shares) | 1.2 | 0.7 | 1 | 0.9 |
Weighted average shares outstanding-diluted | 158.7 | 161.5 | 159.9 | 162.7 |
Net income per common share attributable to Bruker Corporation shareholders: | ||||
Basic (in dollars per share) | $ 0.23 | $ 0.29 | $ 0.52 | $ 0.52 |
Diluted (in dollars per share) | $ 0.23 | $ 0.29 | $ 0.51 | $ 0.52 |
Earnings Per Share - Anti-dilut
Earnings Per Share - Anti-dilutive Stock Options (Details) - shares shares in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Stock options | ||||
Anti-dilutive securities | ||||
Number of shares excluded from the computation of diluted earnings per share | 1 | 2.4 | 1.7 | 1.9 |
Fair Value of Financial Instr49
Fair Value of Financial Instruments - Hierarchy (Details) - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 |
Significant Other Observable Inputs (Level 2) | ||
Liabilities: | ||
Fair value of long-term fixed interest rate debt | $ 230.3 | $ 253.3 |
Recurring basis | ||
Assets: | ||
Embedded derivatives in purchase and delivery contracts | 0.9 | 4 |
Foreign exchange contracts | 4.4 | |
Fixed price commodity contracts | 0.7 | 0.2 |
Total assets recorded at fair value | 6 | 4.2 |
Liabilities: | ||
Contingent consideration | 12.3 | 16.6 |
Foreign exchange contracts | 0.3 | 1.4 |
Embedded derivatives in purchase and delivery contracts | 2.2 | 0.3 |
Total liabilities recorded at fair value | 14.8 | 18.3 |
Recurring basis | Significant Other Observable Inputs (Level 2) | ||
Assets: | ||
Embedded derivatives in purchase and delivery contracts | 0.9 | 4 |
Foreign exchange contracts | 4.4 | |
Fixed price commodity contracts | 0.7 | 0.2 |
Total assets recorded at fair value | 6 | 4.2 |
Liabilities: | ||
Foreign exchange contracts | 0.3 | 1.4 |
Embedded derivatives in purchase and delivery contracts | 2.2 | 0.3 |
Total liabilities recorded at fair value | 2.5 | 1.7 |
Recurring basis | Significant Unobservable Inputs (Level 3) | ||
Liabilities: | ||
Contingent consideration | 12.3 | 16.6 |
Total liabilities recorded at fair value | $ 12.3 | $ 16.6 |
Fair Value of Financial Instr50
Fair Value of Financial Instruments - Time and Call Deposits (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2017 | Dec. 31, 2016 | |
Investments in time and call deposits | ||
Period of ability to redeem invested amounts on call deposits | 95 days | |
Cash equivalents | $ 0 | |
Restricted cash | 3.8 | $ 3.5 |
Short-term investments | $ 165.3 | $ 157.9 |
Minimum | ||
Investments in time and call deposits | ||
Maturity of time deposits | 1 month | |
Maximum | ||
Investments in time and call deposits | ||
Maturity of time deposits | 12 months |
Fair Value of Financial Instr51
Fair Value of Financial Instruments - Contingent Consideration (Details) - Contingent consideration $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Changes in contingent consideration liabilities | |
Balance at the beginning of the period | $ 16.6 |
Current period additions | 5 |
Current period adjustments | 2 |
Current period settlements | (11.7) |
Foreign currency effect | 0.4 |
Balance at the end of the period | $ 12.3 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 |
Inventories | ||
Raw materials | $ 154 | $ 132.8 |
Work-in-process | 203.2 | 181 |
Finished goods | 108.4 | 91.8 |
Demonstration units | 49.7 | 34.8 |
Inventories | 515.3 | 440.4 |
Inventory-in-transit | $ 44.1 | $ 37.5 |
Goodwill and Other Intangible53
Goodwill and Other Intangible Assets - Goodwill (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Goodwill | |
Balance at the beginning of the period | $ 130.6 |
Goodwill acquired during the period | 33.4 |
Foreign currency effect | 4.6 |
Balance at the end of the period | $ 168.6 |
Goodwill and Other Intangible54
Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | |
Intangible assets | |||||
Gross Carrying Amount, intangible assets subject to amortization | $ 235.2 | $ 235.2 | $ 192.4 | ||
Accumulated Amortization, intangible assets subject to amortization | (146.8) | (146.8) | (123.3) | ||
Net Carrying Amount, intangible assets subject to amortization | 88.4 | 88.4 | 69.1 | ||
Gross Carrying Amount, total intangible assets | 235.8 | 235.8 | 193 | ||
Net Carrying Amount, total intangible assets | 89 | 89 | 69.7 | ||
Amortization expense related to intangible assets subject to amortization | 8.2 | $ 5.4 | 22.6 | $ 16.2 | |
In-process research and development | |||||
Intangible assets | |||||
Gross Carrying Amount, intangible assets not subject to amortization | 0.6 | 0.6 | 0.6 | ||
Net Carrying Amount, intangible assets not subject to amortization | 0.6 | 0.6 | 0.6 | ||
Existing technology and related patents | |||||
Intangible assets | |||||
Gross Carrying Amount, intangible assets subject to amortization | 194.8 | 194.8 | 169 | ||
Accumulated Amortization, intangible assets subject to amortization | (133) | (133) | (113.9) | ||
Net Carrying Amount, intangible assets subject to amortization | 61.8 | 61.8 | 55.1 | ||
Customer relationships | |||||
Intangible assets | |||||
Gross Carrying Amount, intangible assets subject to amortization | 34.4 | 34.4 | 20 | ||
Accumulated Amortization, intangible assets subject to amortization | (11.7) | (11.7) | (7.9) | ||
Net Carrying Amount, intangible assets subject to amortization | 22.7 | 22.7 | 12.1 | ||
Non compete contracts | |||||
Intangible assets | |||||
Gross Carrying Amount, intangible assets subject to amortization | 1.8 | 1.8 | 1.8 | ||
Accumulated Amortization, intangible assets subject to amortization | (1.4) | (1.4) | (1.1) | ||
Net Carrying Amount, intangible assets subject to amortization | 0.4 | 0.4 | 0.7 | ||
Trade names | |||||
Intangible assets | |||||
Gross Carrying Amount, intangible assets subject to amortization | 4.2 | 4.2 | 1.6 | ||
Accumulated Amortization, intangible assets subject to amortization | (0.7) | (0.7) | (0.4) | ||
Net Carrying Amount, intangible assets subject to amortization | $ 3.5 | $ 3.5 | $ 1.2 |
Debt - Components (Details)
Debt - Components (Details) - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 |
Debt | ||
Total debt | $ 480.5 | $ 411.7 |
Current portion of long-term debt | (20.1) | |
Total long-term debt, less current portion | 480.5 | 391.6 |
US Dollar notes under the Note Purchase Agreement | ||
Debt | ||
Debt, before unamortized debt issuance costs | 220 | 240 |
Unamortized debt issuance costs | (0.7) | (0.8) |
Capital lease obligations and other loans | ||
Debt | ||
Total debt | 1.2 | 1.5 |
2015 Credit Agreement | US Dollar revolving loan | ||
Debt | ||
Total debt | $ 260 | $ 171 |
Debt - Credit Agreements (Detai
Debt - Credit Agreements (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Revolving lines of credit | |
Maximum commitment | $ 754.7 |
2015 Credit Agreement | US Dollar revolving loan | |
Revolving lines of credit | |
Maximum commitment | $ 500 |
Maximum leverage ratio allowed | 3.5 |
Minimum interest coverage ratio required | 2.5 |
2015 Credit Agreement | US Dollar revolving loan | Minimum | |
Revolving lines of credit | |
Facility fee (as a percent) | 0.10% |
2015 Credit Agreement | US Dollar revolving loan | Maximum | |
Revolving lines of credit | |
Facility fee (as a percent) | 0.20% |
2015 Credit Agreement | US Dollar revolving loan | Greatest of prime rate, federal funds rate plus spread and adjusted LIBOR plus spread | Minimum | |
Revolving lines of credit | |
Interest rate added to base rate (as a percent) | 0.00% |
2015 Credit Agreement | US Dollar revolving loan | Greatest of prime rate, federal funds rate plus spread and adjusted LIBOR plus spread | Maximum | |
Revolving lines of credit | |
Interest rate added to base rate (as a percent) | 0.30% |
2015 Credit Agreement | US Dollar revolving loan | Prime rate | |
Revolving lines of credit | |
Variable interest rate base | prime rate |
2015 Credit Agreement | US Dollar revolving loan | Federal funds rate | |
Revolving lines of credit | |
Variable interest rate base | federal funds rate |
Interest rate added to base rate (as a percent) | 0.50% |
2015 Credit Agreement | US Dollar revolving loan | Adjusted LIBOR | |
Revolving lines of credit | |
Variable interest rate base | adjusted LIBOR |
Interest rate added to base rate (as a percent) | 1.00% |
2015 Credit Agreement | US Dollar revolving loan | LIBOR | |
Revolving lines of credit | |
Variable interest rate base | LIBOR |
2015 Credit Agreement | US Dollar revolving loan | LIBOR | Minimum | |
Revolving lines of credit | |
Interest rate added to base rate (as a percent) | 0.90% |
2015 Credit Agreement | US Dollar revolving loan | LIBOR | Maximum | |
Revolving lines of credit | |
Interest rate added to base rate (as a percent) | 1.30% |
Debt - Revolving Loan Arrangeme
Debt - Revolving Loan Arrangements (Details) $ in Millions | Sep. 30, 2017USD ($) |
Revolving lines of credit | |
Total Amount Committed by Lenders | $ 754.7 |
Outstanding Borrowings | 260 |
Outstanding Letters of Credit | 124 |
Total Amount Available | 370.7 |
Other lines of credit | |
Revolving lines of credit | |
Total Amount Committed by Lenders | 254.7 |
Outstanding Letters of Credit | 122.9 |
Total Amount Available | $ 131.8 |
2015 Credit Agreement | US Dollar revolving loan | |
Revolving lines of credit | |
Weighted Average Interest Rate (as a percent) | 2.30% |
Total Amount Committed by Lenders | $ 500 |
Outstanding Borrowings | 260 |
Outstanding Letters of Credit | 1.1 |
Total Amount Available | $ 238.9 |
Debt - Senior Notes (Details)
Debt - Senior Notes (Details) $ in Millions | Jan. 18, 2017USD ($) | Sep. 30, 2017USD ($) | Jan. 31, 2012USD ($) |
Debt | |||
Principal repayment of Senior Notes | $ 20 | ||
US Dollar notes under the Note Purchase Agreement | |||
Debt | |||
Senior notes | $ 240 | ||
Additional aggregate principal amount that may be issued | $ 600 | ||
Minimum percentage of original aggregate principal that may be prepaid | 10.00% | ||
Prepayment price as percentage of principal amount | 100.00% | ||
Prepayment price as percentage of principal amount, in the event of a change in control | 100.00% | ||
Maximum leverage ratio allowed | 3.50 | ||
Period for interest coverage ratio | 1 year | ||
Minimum interest coverage ratio required | 2.50 | ||
Priority debt as a percentage of consolidated net worth | 25.00% | ||
US Dollar notes under the Note Purchase Agreement | Minimum | |||
Debt | |||
Written notice period to holders of the Notes | 30 days | ||
US Dollar notes under the Note Purchase Agreement | Maximum | |||
Debt | |||
Written notice period to holders of the Notes | 60 days | ||
3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017 | US Dollar notes under the Note Purchase Agreement | |||
Debt | |||
Senior notes | $ 20 | ||
Interest rate, stated percentage | 3.16% | ||
Principal repayment of Senior Notes | $ 20 | ||
3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019 | US Dollar notes under the Note Purchase Agreement | |||
Debt | |||
Senior notes | $ 15 | ||
Interest rate, stated percentage | 3.74% | ||
4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022 | US Dollar notes under the Note Purchase Agreement | |||
Debt | |||
Senior notes | $ 105 | ||
Interest rate, stated percentage | 4.31% | ||
4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024 | US Dollar notes under the Note Purchase Agreement | |||
Debt | |||
Senior notes | $ 100 | ||
Interest rate, stated percentage | 4.46% |
Debt - Covenant Compliance (Det
Debt - Covenant Compliance (Details) - Note Purchase Agreement and 2015 Credit Agreement | 9 Months Ended |
Sep. 30, 2017 | |
Debt | |
Actual leverage ratio | 1.61 |
Actual interest coverage ratio | 14.8 |
Derivative Instruments and He60
Derivative Instruments and Hedging Activities - Risk Management (Details) € in Millions, ₪ in Millions, SFr in Millions, $ in Millions | Sep. 30, 2017CHF (SFr) | Sep. 30, 2017EUR (€) | Sep. 30, 2017USD ($) | Dec. 31, 2016CHF (SFr) | Dec. 31, 2016ILS (₪) | Dec. 31, 2016EUR (€) | Dec. 31, 2016USD ($) |
Derivative instruments and hedging activities | |||||||
Credit agreement, amount outstanding | $ 260 | ||||||
Embedded derivatives in purchase and delivery contracts | |||||||
Derivative instruments and hedging activities | |||||||
Notional amount of derivative sale contracts | 90.4 | $ 120.7 | |||||
Notional amount of derivative purchase contracts | 2.4 | 2.3 | |||||
Fixed price commodity contracts | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | 4.7 | 2.7 | |||||
Not designated as hedging instruments | Foreign exchange contracts | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | 101.3 | 40.7 | |||||
Fair Value of Assets | 4.4 | ||||||
Fair Value of Liabilities | 0.3 | 1.4 | |||||
Not designated as hedging instruments | US Dollar:EUR | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | € 71.4 | 80.3 | € 21.1 | 23.3 | |||
Fair Value of Assets | 4.3 | ||||||
Fair Value of Liabilities | 1.1 | ||||||
Not designated as hedging instruments | EUR:US Dollar | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | 8 | ||||||
Fair Value of Assets | 0.1 | ||||||
Not designated as hedging instruments | US Dollar:CHF | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | SFr 10.3 | 10.9 | SFr 7.9 | 8 | |||
Fair Value of Liabilities | 0.3 | 0.3 | |||||
Not designated as hedging instruments | ILS:US Dollar | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | 4 | ||||||
Not designated as hedging instruments | US Dollar:ILS | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | ₪ 15.3 | 4 | |||||
Not designated as hedging instruments | PLN:EUR | |||||||
Derivative instruments and hedging activities | |||||||
Notional Amount | € 1.8 | 2.1 | € 1.4 | $ 1.4 | |||
2015 Credit Agreement | US Dollar revolving loan | |||||||
Derivative instruments and hedging activities | |||||||
Credit agreement, amount outstanding | $ 260 |
Derivative Instruments and He61
Derivative Instruments and Hedging Activities - Fair Values (Details) - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 |
Foreign exchange contracts | Other current assets | ||
Derivative instruments and hedging activities | ||
Derivative assets | $ 4.4 | |
Foreign exchange contracts | Other current liabilities | ||
Derivative instruments and hedging activities | ||
Derivative liabilities | 0.3 | $ 1.4 |
Embedded derivatives in purchase and delivery contracts | Other current assets | ||
Derivative instruments and hedging activities | ||
Derivative assets | 0.9 | 2.7 |
Embedded derivatives in purchase and delivery contracts | Other long-term assets | ||
Derivative instruments and hedging activities | ||
Derivative assets | 1.3 | |
Embedded derivatives in purchase and delivery contracts | Other current liabilities | ||
Derivative instruments and hedging activities | ||
Derivative liabilities | 1.2 | 0.3 |
Embedded derivatives in purchase and delivery contracts | Other long-term liabilities | ||
Derivative instruments and hedging activities | ||
Derivative liabilities | 1 | |
Fixed price commodity contracts | Other current assets | ||
Derivative instruments and hedging activities | ||
Derivative assets | $ 0.7 | $ 0.2 |
Derivative Instruments and He62
Derivative Instruments and Hedging Activities - Gains and Losses (Details) - Not designated as hedging instruments - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Derivative instruments and hedging activities | ||||
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments | $ (2.5) | $ 1 | $ 1 | $ 1.5 |
Foreign exchange contracts | ||||
Derivative instruments and hedging activities | ||||
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments | (1.5) | 0.7 | 5.5 | 1.3 |
Embedded derivatives in purchase and delivery contracts | ||||
Derivative instruments and hedging activities | ||||
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments | (1.3) | $ 0.3 | (5) | |
Fixed price commodity contracts | ||||
Derivative instruments and hedging activities | ||||
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments | $ 0.3 | $ 0.5 | $ 0.2 |
Provision for Income Taxes (Det
Provision for Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Provision for Income Taxes | ||||||
Income tax provision | $ 9.8 | $ (4) | $ 25.9 | $ 3.8 | ||
Effective tax rates (as a percent) | 20.70% | (9.30%) | 23.70% | 4.30% | ||
Unrecognized tax benefits, excluding penalties and interest | $ 6.1 | $ 6.1 | $ 6.2 | |||
Portion of unrecognized tax benefits, which if recognized, would result in a reduction of the effective tax rate | 5.2 | 5.2 | 5.3 | |||
Accrued interest and penalties related to uncertain tax positions | 0.5 | 0.5 | $ 0.5 | |||
Penalties and interest expense relating to unrecognized tax benefits | $ 0 | $ 0.9 | $ 0 | $ 1.5 | ||
Expected | ||||||
Provision for Income Taxes | ||||||
US statutory rate (as a percent) | 35.00% | |||||
Expected | Germany and Switzerland | ||||||
Provision for Income Taxes | ||||||
Reduction in effective tax rate from impact of foreign statutory rates (as a percent) | 8.80% | |||||
Expected | Germany | Foreign | ||||||
Provision for Income Taxes | ||||||
Foreign statutory tax rate for 2017 (as a percent) | 28.00% | |||||
Expected | Switzerland | Foreign | ||||||
Provision for Income Taxes | ||||||
Foreign statutory tax rate for 2017 (as a percent) | 20.50% |
Commitments and Contingencies -
Commitments and Contingencies - Litigation, Governmental Investigations (Details) | 1 Months Ended | 12 Months Ended | |||
Dec. 31, 2016 | Sep. 30, 2016USD ($) | Dec. 31, 2016 | Sep. 30, 2017USD ($) | May 30, 2017item | |
KFTC investigation | |||||
Contingencies | |||||
Number of bids under investigation | item | 3 | ||||
Fine assessed | $ 15,000 | ||||
Accruals for additional payments | $ 0 | ||||
Minimum | KFTC investigation | |||||
Contingencies | |||||
Period of suspension or restriction | 3 months | ||||
Maximum | Korea | |||||
Contingencies | |||||
Sales to governmental agencies as a percentage of total revenue | 1.00% | ||||
Maximum | KFTC investigation | |||||
Contingencies | |||||
Period of suspension or restriction | 6 months |
Commitments and Contingencies65
Commitments and Contingencies - Guarantees (Details) - USD ($) $ in Millions | Sep. 30, 2017 | Dec. 31, 2016 |
Letters of Credit and Guarantees | ||
Bank guarantees primarily for customer advances | $ 124 | |
Revolving Loans | ||
Letters of Credit and Guarantees | ||
Bank guarantees primarily for customer advances | $ 124 | $ 131.5 |
Shareholders' Equity - Share Re
Shareholders' Equity - Share Repurchase and Dividends (Details) - USD ($) $ / shares in Units, $ in Millions | Sep. 22, 2017 | Jun. 23, 2017 | Mar. 24, 2017 | Feb. 22, 2016 | Nov. 06, 2017 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 |
Shareholders' Equity | |||||||||
Dividend declared (in dollars per share) | $ 0.04 | $ 0.04 | $ 0.04 | $ 0.12 | $ 0.12 | ||||
Target dividend per annum (in dollars per share) | $ 0.16 | ||||||||
Dividends paid, aggregate cost | $ 6.3 | $ 6.4 | $ 6.4 | $ 19.1 | $ 19.4 | ||||
May 2017 Repurchase Program | |||||||||
Shareholders' Equity | |||||||||
Amount approved for repurchase of common stock | $ 225 | $ 225 | |||||||
Common stock repurchased during the period (in shares) | 3,063,133 | 4,658,063 | |||||||
Aggregate cost of common stock repurchased during the period | $ 87.9 | $ 131.8 | |||||||
May 2017 Repurchase Program | Subsequent Event | |||||||||
Shareholders' Equity | |||||||||
Common stock repurchased during the period (in shares) | 660,000 | ||||||||
Aggregate cost of common stock repurchased during the period | $ 20.4 |
Shareholders' Equity - Comprehe
Shareholders' Equity - Comprehensive Income (loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Summary of comprehensive income | ||||
Consolidated net income | $ 37.6 | $ 47 | $ 83.3 | $ 85.4 |
Foreign currency translation adjustments | 21.9 | 12.7 | 87 | 27.7 |
Pension liability adjustments, net of tax | 1.7 | 0.6 | 1.2 | |
Net comprehensive income | 61.2 | 60.3 | 170.3 | 114.3 |
Less: Comprehensive income attributable to noncontrolling interests | 0.7 | 0.6 | 1.9 | 0.9 |
Comprehensive income attributable to Bruker Corporation | $ 60.5 | $ 59.7 | $ 168.4 | $ 113.4 |
Shareholders' Equity - Accumula
Shareholders' Equity - Accumulated Other Comprehensive Income (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Summary of the components of accumulated other comprehensive income (loss), net of tax | |
Balance at beginning of period | $ (75.9) |
Balance at end of period | 10.5 |
Accumulated Other Comprehensive Income (Loss) | |
Summary of the components of accumulated other comprehensive income (loss), net of tax | |
Balance at beginning of period | (75.9) |
Other comprehensive income (loss) before reclassifications | 83.5 |
Amounts reclassified from other comprehensive income (loss), net of tax of $0.4 million | 2.9 |
Net current period other comprehensive income | 86.4 |
Balance at end of period | 10.5 |
Amount from reclassification, tax | 0.4 |
Foreign Currency Translation | |
Summary of the components of accumulated other comprehensive income (loss), net of tax | |
Balance at beginning of period | (24.1) |
Other comprehensive income (loss) before reclassifications | 86.4 |
Net current period other comprehensive income | 86.4 |
Balance at end of period | 62.3 |
Pension Liability Adjustment | |
Summary of the components of accumulated other comprehensive income (loss), net of tax | |
Balance at beginning of period | (51.8) |
Other comprehensive income (loss) before reclassifications | (2.9) |
Amounts reclassified from other comprehensive income (loss), net of tax of $0.4 million | 2.9 |
Balance at end of period | (51.8) |
Amount from reclassification, tax | $ 0.4 |
Noncontrolling Interests (Detai
Noncontrolling Interests (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Noncontrolling interests | ||||
Balance at beginning of period | $ 7.4 | $ 7.1 | $ 6.7 | $ 6.8 |
Net income | 0.6 | 0.5 | 1.3 | 0.8 |
Foreign currency translation adjustments | 0.1 | 0.1 | 0.6 | 0.1 |
Cash payments to noncontrolling interest | (0.7) | (0.5) | (0.7) | |
Balance at end of period | $ 8.1 | $ 7 | $ 8.1 | $ 7 |
Other Charges, Net - Components
Other Charges, Net - Components (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Other Charges, Net | ||||
Information technology transformation costs | $ 0.8 | $ 1.6 | $ 2.9 | $ 5.5 |
Restructuring charges | 3 | 2.8 | 6.9 | 6.4 |
Acquisition-related charges | 0.5 | 0.2 | 3.8 | 8.1 |
Other | 0.2 | 0.6 | ||
Other charges, net | $ 4.3 | $ 4.6 | $ 13.8 | $ 20.6 |
Other Charges, Net - Restructur
Other Charges, Net - Restructuring Initiatives (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017USD ($) | Sep. 30, 2016USD ($) | Sep. 30, 2017USD ($)employee | Sep. 30, 2016USD ($) | |
Restructuring charges | ||||
Restructuring expenses | $ 8.6 | |||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | ||||
Restructuring charges | ||||
Expected reduction in number of employees | employee | 125 | |||
Restructuring expenses | $ 2.1 | $ 6.1 | $ 5.9 | $ 6.1 |
Restructuring and other one-time charges incurred to date | 16.3 | 16.3 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Cost of revenues | ||||
Restructuring charges | ||||
Restructuring expenses | 1.3 | 3.5 | 3.5 | 3.5 |
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Other charges, net | ||||
Restructuring charges | ||||
Restructuring expenses | 0.8 | 2.6 | 2.4 | 2.6 |
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Severance and Exit Costs | ||||
Restructuring charges | ||||
Restructuring expenses | 1.9 | 5.4 | 5.4 | 5.4 |
Restructuring and other one-time charges incurred to date | 13.2 | 13.2 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Severance and Exit Costs | Cost of revenues | ||||
Restructuring charges | ||||
Restructuring expenses | 1.1 | 3 | 3 | 3 |
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Severance and Exit Costs | Other charges, net | ||||
Restructuring charges | ||||
Restructuring expenses | 0.8 | 2.4 | 2.4 | 2.4 |
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Inventory Writedown and Asset Impairment | ||||
Restructuring charges | ||||
Restructuring expenses | 0.2 | 0.7 | 0.5 | 0.7 |
Restructuring and other one-time charges incurred to date | 3.1 | 3.1 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Inventory Writedown and Asset Impairment | Cost of revenues | ||||
Restructuring charges | ||||
Restructuring expenses | 0.2 | 0.5 | 0.5 | 0.5 |
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Inventory Writedown and Asset Impairment | Other charges, net | ||||
Restructuring charges | ||||
Restructuring expenses | 0.2 | 0.2 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Minimum | ||||
Restructuring charges | ||||
Expected restructuring and related one-time charges | 17 | 17 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Minimum | Severance and Exit Costs | ||||
Restructuring charges | ||||
Expected restructuring and related one-time charges | 16 | 16 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Minimum | Inventory Writedown and Asset Impairment | ||||
Restructuring charges | ||||
Expected restructuring and related one-time charges | 1 | 1 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Maximum | ||||
Restructuring charges | ||||
Expected restructuring and related one-time charges | 19 | 19 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Maximum | Severance and Exit Costs | ||||
Restructuring charges | ||||
Expected restructuring and related one-time charges | 17.5 | 17.5 | ||
Restructuring initiative within Bruker CALID and Bruker Nano Groups | Maximum | Inventory Writedown and Asset Impairment | ||||
Restructuring charges | ||||
Expected restructuring and related one-time charges | $ 1.5 | $ 1.5 | ||
Restructuring initiative within Bruker BioSpin Group | ||||
Restructuring charges | ||||
Reduction in employee headcount (as a percent) | 9.00% | 9.00% | ||
Restructuring expenses | $ 0 | 0 | $ (2.7) | 3.3 |
Restructuring initiative within Bruker BioSpin Group | Cost of revenues | ||||
Restructuring charges | ||||
Restructuring expenses | (2.7) | 2.2 | ||
Restructuring initiative within Bruker BioSpin Group | Other charges, net | ||||
Restructuring charges | ||||
Restructuring expenses | 1.1 | |||
Restructuring initiative within Bruker BioSpin Group | Severance and Exit Costs | ||||
Restructuring charges | ||||
Restructuring expenses | (2.7) | 3.3 | ||
Restructuring initiative within Bruker BioSpin Group | Severance and Exit Costs | Cost of revenues | ||||
Restructuring charges | ||||
Restructuring expenses | (2.7) | 2.2 | ||
Restructuring initiative within Bruker BioSpin Group | Severance and Exit Costs | Other charges, net | ||||
Restructuring charges | ||||
Restructuring expenses | 1.1 | |||
Other programs | ||||
Restructuring charges | ||||
Restructuring expenses | 2.5 | 1.2 | 5.3 | 3.4 |
Other programs | Cost of revenues | ||||
Restructuring charges | ||||
Restructuring expenses | 0.3 | 1 | 0.8 | 0.7 |
Other programs | Other charges, net | ||||
Restructuring charges | ||||
Restructuring expenses | $ 2.2 | $ 0.2 | $ 4.5 | $ 2.7 |
Other Charges, Net - Restruct72
Other Charges, Net - Restructuring Reserves (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Changes in the restructuring reserves | |
Balance at the beginning of the period | $ 16.2 |
Restructuring charges | 8.6 |
Cash payments | (12.7) |
Other, non-cash adjustments and foreign currency effect | (1.7) |
Balance at the end of the period | 10.4 |
Severance | |
Changes in the restructuring reserves | |
Balance at the beginning of the period | 4.9 |
Restructuring charges | 6.4 |
Cash payments | (7.9) |
Other, non-cash adjustments and foreign currency effect | (0.1) |
Balance at the end of the period | 3.3 |
Exit Costs | |
Changes in the restructuring reserves | |
Balance at the beginning of the period | 3.7 |
Restructuring charges | 2.1 |
Cash payments | (4.6) |
Other, non-cash adjustments and foreign currency effect | (0.3) |
Balance at the end of the period | 0.9 |
Provisions for Excess Inventory | |
Changes in the restructuring reserves | |
Balance at the beginning of the period | 7.6 |
Restructuring charges | 0.1 |
Cash payments | (0.2) |
Other, non-cash adjustments and foreign currency effect | (1.3) |
Balance at the end of the period | $ 6.2 |
Interest and Other Income (Ex73
Interest and Other Income (Expense), Net (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Interest and Other Income (Expense), Net | ||||
Interest expense, net | $ (3.6) | $ (3.4) | $ (11.1) | $ (9.4) |
Exchange gains (losses) on foreign currency transactions | 0.3 | (3.9) | (1.6) | |
Other | 0.8 | 0.5 | 3.2 | (0.1) |
Interest and other income (expense), net | $ (2.5) | $ (2.9) | $ (11.8) | $ (11.1) |
Business Segment Information (D
Business Segment Information (Details) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2017USD ($) | Sep. 30, 2016USD ($) | Sep. 30, 2017USD ($)segment | Sep. 30, 2016USD ($) | Dec. 31, 2016USD ($) | |
Business segment information | |||||
Number of reportable segments | segment | 2 | ||||
Revenue | $ 435.6 | $ 393.9 | $ 1,235.4 | $ 1,141 | |
Operating income | 49.9 | 45.9 | 121 | 100.3 | |
Assets | 1,961.5 | 1,961.5 | $ 1,808.4 | ||
Eliminations | |||||
Business segment information | |||||
Revenue | (1.1) | (3.1) | (4.3) | (7.8) | |
Corporate, eliminations and other | |||||
Business segment information | |||||
Operating income | 5 | (0.1) | 5 | 0.9 | |
Assets | (2) | (2) | (7.4) | ||
BSI | Operating segments | |||||
Business segment information | |||||
Revenue | 390.6 | 361.5 | 1,099.5 | 1,057.6 | |
Operating income | 43.1 | 43.3 | 111.7 | 95.3 | |
Assets | 1,929.4 | 1,929.4 | 1,779.8 | ||
BEST | Operating segments | |||||
Business segment information | |||||
Revenue | 46.1 | 35.5 | 140.2 | 91.2 | |
Operating income | 1.8 | $ 2.7 | 4.3 | $ 4.1 | |
Assets | $ 34.1 | $ 34.1 | $ 36 |